



US 20050153295A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2005/0153295 A1**
Von Der Kammer et al. (43) **Pub. Date: Jul. 14, 2005**(54) **DIAGNOSTIC AND THERAPEUTIC USE OF
HUMAN MAGUIN PROTEINS AND NUCLEIC
ACIDS FOR NEURODEGENERATIVE
DISEASES**(76) Inventors: **Heinz Von Der Kammer**, Hamburg
(DE); **Jozef Hanes**, Schenefeld (DE);
Johannes Pohlner, Hamburg (DE)Correspondence Address:
JACOBSON HOLMAN PLLC
400 SEVENTH STREET N.W.
SUITE 600
WASHINGTON, DC 20004 (US)(21) Appl. No.: **10/508,343**(22) PCT Filed: **Mar. 19, 2003**(86) PCT No.: **PCT/EP03/02857****Related U.S. Application Data**(60) Provisional application No. 60/365,815, filed on Mar.
21, 2002.(30) **Foreign Application Priority Data**

Mar. 21, 2002 (EP) 02006353.3

Publication Classification(51) **Int. Cl.⁷** **C12Q 1/68**; G01N 33/53;
G01N 33/567(52) **U.S. Cl.** **435/6**; 435/7.2(57) **ABSTRACT**

The present invention discloses the differential expression of the human MAGUIN-1 and/or human MAGUIN-2 gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using a human MAGUIN gene. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

**Fig. 1: Identification of Genes Involved
in Alzheimer's Disease Pathology**




Fig. 2: Identification of differentially expressed genes in a fluorescence differential display screen




Fig. 3: Verification of differential expression of human MAGUIN-1 by quantitative RT-PCR




Fig. 4: Verification of differential expression of Maguin-1 by quantitative RT-PCR




Fig. 5: Verification of differential expression of human MAGUIN-2 by quantitative RT-PCR




Fig. 6: Verification of differential expression of Maguin-2 by quantitative RT-PCR




Fig. 7: SEQ ID NO. 1:
amino acid sequence of
human MAGUIN-1 protein

Length: 1034 aa

1 MALIMEPVSK WSPSQVVDWM KGLDDCLQQY IKNFEREKIS GDQLLRITHQ
51 ELEDLGVSRI GHQELILEAV DLLCALNYGL ETENLKTLSH KLNASAKNLQ
101 NFITGRRRSRSG HYDGRTSRKL PNDFLTSTVVD LIGAAKSLLA WLDRSPFAAV
151 TDYSVTRNNV IQLCLELTTI VQQDCTVYET ENKILHVCKT LSGVCDHIIS
201 LSSDPLVSQS AHLEVIQLAN IKPSEGLGMY IKSTYDGLHV ITGTTENSPA
251 DRCKKIHAGD EVIQVNHQTV VGWQLKNLVN ALREDPSGVI LTLKKRPQSM
301 LTSAPALLKN MRWKPLALQP LIPRSPTSSV ATPSSTISTP TKRDSSALQD
351 LYIPPPPAEP YIPRDEKGNL PCEDLRGHMV GKPVHKGSES PNSFLDQEYR
401 KRFNIVEEDT VLYCYEYEKG RSSSQGRRES TPTYGKLRPI SMPVEYNWVG
451 DYEDPNKMKR DSRRENLLR YMSNEKIAQE EYMFQRNSKK DTGKSKKKKG
501 DKSNSPTHYS LLPSLQMDAL RQDIMGTPVP ETTLYHTFQQ SSLQHKSXXX
551 NKGPIAGKSK RRISCKDLGR GDCEGWLWKK KDAKSYFSQK WKKYWFVLKD
601 ASLYWYINEE DEKAEGFISL PEFKIDRASE CRKKAFAKAC HPKIKSFYFA
651 AEHLDDMNRW LNRINMLTAG YAEERERIKQE QDYWSESDKE EADTPSTPKQ
701 DSPPPPYDTY PRPPSMSCAS PYVEAKHSRL SSTETSQSQS SHEEFRQEV
751 GSSAVSPIRK TASQRRSWQD LIETPLTSSG LHYLQTLPLE DSVFSDSAI
801 SPEHRRQSTL PTQKCHLQDH YGPYPLAESE RMQVLNGNGG KPRSFTLPRD
851 SGFNHCCLNA PVSACDPQDD VQPPEVEEEE EEEEEGEAA GENIGEKSES
901 REEKLGDSLQ DLYRALEQAS LSPLGEHRIS TKMEYKLSFI KRCNDPVMNE
951 KLHRLRILKS TLKAREGEVA IIDKVLDNPD LTSKEFQQWK QMYLDLFLDI
1001 CQNTTSNDPL SISSEVDVIT SSLAHTHSYI ETHV*

Length: 1034 aa

1	MALIMEPVSKWSPSQVVDWMKGLDDCLQQYIKNFEREKISGDQLLRITHQ	50
1	MALIMEPVSKWSPSQVVDWMKGLDDCLQQYIKNFEREKISGDQLLRITHQ	50
51	ELEDLGVSRIHQELILEAVDLLCALNYGLETENLKTLSHKLNASAKNLQ	100
51	ELEDLGVSRIHQELILEAVDLLCALNYGLETENLKTLSHKLNASAKNLQ	100
101	NFITGRRRSGHYDGRTSRKLPNDFLTSVVDLIGAAKSLLAWLDRSPFAAV	150
101	NFITGRRRSGHYDGRTSRKLPNDFLTSVVDLIGAAKSLLAWLDRSPFAAV	150
151	TDYSVTRNNVIQLCLELTTIVQQDCTVYETENKILHVCKTSLSGVCDHIIS	200
151	TDYSVTRNNVIQLCLELTTIVQQDCTVYETENKILHVCKTSLSGVCDHIIS	200
201	LSSDPLVSQSAHLEVIQLANIKPSEGLGMYIKSTYDGLHVITGTTENSPA	250
201	LSSDPLVSQSAHLEVIQLANIKPSEGLGMYIKSTYDGLHVITGTTENSPA	250
251	DRCKKIHAGDEVIQVNHQTVVGWQLKNLVNALREDPSGVILTLLKKRPQSM	300
251	DRCKKIHAGDEVIQVNHQTVVGWQLKNLVNALREDPSGVILTLLKKRPQSM	300
301	LTSAPALLKNMRWKPLALQPLIPRSPTSSVATPSSTISTPTKRDSSALQD	350
301	LTSAPALLKNMRWKPLALQPLIPRSPTSSVATPSSTISTPTKRDSSALQD	350
351	LYIPPPPAEPIYIPRDEKGNLPCEDLRGHMVGKPVHKGSESPNSFLDQEYR	400
351	LYIPPPPAEPIYIPRDEKGNLPCEDLRGHMVGKPVHKGSESPNSFLDQEYR	400
401	KRFNIVEEDTVLYCYEYEKGRSSSQGRRESTPTYGKLRPISMPVEYNWVG	450
401	KRFNIVEEDTVLYCYEYEKGRSSSQGRRESTPTYGKLRPISMPVEYNWVG	450
451	DYEDPNKMKRDSRRENSLLRYMSNEKIAQEEYMFQNSKKDTGKKSCKKKG	500
451	DYEDPNKMKRDSRRENSLLRYMSNEKIAQEEYMFQNSKKDTGKKSCKKKG	500

501 DKSNSPTHYSLLPSLQMDALRQDIMGTPVPETTLYHTFQQSSLQHKSKKK 550
|||:|||||||||||||||||||||||||||||||||||||
501 DKSTSPTHYSLLPSLQMDALRQDIMGTPVPETTLYHTFQQSSLQHKSKKK 550
551 NKGPIAGKSKRRISCKDLGRGDCEGWLWKKKDAKSYFSQKWKYWFVLKD 600
|||:|||||||||||||||||||||||||||||||||||||
551 NKGAIAGKSKRRISCKDLGRGDCEGWLWKKKDAKSYFSQKWKYWFVLKD 600
601 ASLYWYINEEDEKAEGFISLPEFKIDRASECRKKYAFKACHPKIKSFYFA 650
|||||||||||||||||||||||||||||||||||||
601 ASLYWYINEEDEKAEGFISLPEFKIDRASECRKKYAFKACHPKIKSFYFA 650
651 AEHLDDMNRLNRLNMLTAGYAERERIKQEQDYWSESDKEEADTPSTPKQ 700
|||||||||||||||||||||||||||||||||||||
651 AEHLDDMNRLNRLNMLTAGYAERERIKQEQDYWSESDKEEADTPSTPKQ 700
701 DSPPPPYDTPRPPSMSCASPYVEAKHSRLSSTETSQSQSSHEEFRQEV 750
|||||||||||||||||||||||||||||||||||||
701 DSPPPPYDTPRPPSMSCASPYVEAKHSRLSSTETSQSQSSHEEFRQEV 750
751 GSSAVSPIRKTASQRRSWQDLIETPLTSSGLHYLQTLPLEDSVFSDSA 800
|||||||||||||||||||||||||||||||||||||
751 GSSAVSPIRKTASQRRSWQDLIETPLTSSGLHYLQTLPLEDSVFSDSA 800
801 SPEHRRQSTLPTQKCHLQDHYGPYPLAESERMQVLNNGGKPRSFTLPR 850
|||||||||||||||||||||||||||||||||||||
801 SPEHRRQSTLPTQKCHLQDHYGPYPLAESERMQVLNNGGKPRSFTLPR 850
851 SGFNHCCLNAPVSACDPQDDVQPPEVEEEEEEEEEEEGEAAGENIGEKS 900
|||||||||||||||||||:||||||||||||| |||||:|
851 SGFNHCCLNAPVSACDPQDDIQPPEVEEEEEEEEE..EAAGENIGEKNEN 898
901 REEKLGDLSQDLYRALEQASLSPLGEHRISTKMEYKLSFIKRCNDPVMNE 950
|||||||||||||||:|||||||||||:|||||||||||
899 REEKLGDLSQDLYRALEEASLSPLGEHRISTKIEYKLSFIKRCNDPVMNE 948
951 KLHRLRILKSTLKAREGEVAIIDKVLDNPDLTSEFQQWKQMYLDFLDI 1000
|||||||||||||||||||||||||||||||||||||
949 KLHRLRILKSTLKAREGEVAIIDKVLDNPDLTSEFQQWKQMYLDFLDI 998
1001 CQNTTSNDPLSISSEVDVITSSLAHTHSYIETHV 1034
|||||||||||||||||||:|||||||||||
999 CQNTTSNDPLSISSEVDVITSSLAHTHSYIETHV 1032

Fig. 9: SEQ ID NO. 2: amino acid sequence of human MAGUIN-2 protein

Length: 898 aa

1 MALIMEPVSK WSPSQVVDWM KGLDDCLQY IKNFEREKIS GDQLLRITHQ
51 ELEDLGVSRI GHQELILEAV DLLCALNYGL ETENLKTLSH KLNASAKNLQ
101 NFITGRRRSR HYDGRTSRKL PNDFLTSTVVD LIGAAKSLA WDRSPFAAV
151 TDYSVTRNNV IQLCLELTTI VQQDCTVYET ENKILHVCKT LSGVCDHIS
201 LSSDPLVSQS AHLEVIQLAN IKPSEGLGMY IKSTYDGLHV ITGTTENSPA
251 DRCKKIHAGD EVIQVNHQTV VGWQLKNLVN ALREDPSGVI LTLKKRPQSM
301 LTSAPALLKN MRWKPLALQP LIPRSPTSSV ATPSSTISTP TKRDSSALQD
351 LYIPPPPAEP YIPRDEKGNL PCEDLRGHMV GKPVHKGSES PNSFLDQEYR
401 KRFNIVEEDT VLYCYEYKKG RSSSQGRRES TPTYGKLRPI SMPVEYNWVG
451 DYEDPNKMKR DSRRENSLLR YMSNEKIAQE EYMFQRNSKK DTGKKSKKKG
501 DKSNSPTHYS LLPSLQMDAL RQDIMGTPVP ETTLYHTFQQ SSLQHKSKKK
551 NKGPIAGKSK RRISCKDLGR GDCEGWLWKK KDAKSYFSQK WKKYWFLKD
601 ASLYWYINEE DEKAEGFISL PEFKIDRASE CRKKYAFKAC HPKIKSFYFA
651 AEHLDDMNW LNRINMLTAG YAERERIKQE QDYWSESDKE EADTPSTPKQ
701 DSPPPPYDTY PRPPSMSCAS PYVEAKHSRL SSTETSQSQS SHEEFRQEV
751 GSSAVSPIRK TASQRRSWQD LIETPLTSSG LHYLQTLPLE DSVFSDSAI
801 SPEHRRQSTL PTQKCHLQDH YGPYPLAESE RMQVLNGNGG KPRSFTLPRD
851 SGFNHCCLNA PVSACDPQDD VQPPEVEEEE EEEEEGEAA GENIGES*


```

501 DKSNSPTHYSLLPSLQMDALRQDIMGTPVPETTLTYHTFQQSSLQHKSKKK 550
    |||:||||||||||||||||||||||||||||||||||||||||||
501 DKSTSPTHYSLLPSLQMDALRQDIMGTPVPETTLTYHTFQQSSLQHKSKKK 550

551 NKGPIAGKSKRRISCKDLGRGDCEGWLWKKKDAKSYFSQKWKKYWFVLKD 600
    |||:||||||||||||||||||||||||||||||||||||||||||
551 NKGAIAGKSKRRISCKDLGRGDCEGWLWKKKDAKSYFSQKWKKYWFVLKD 600

601 ASLYWYINEEDEKAEGFISLPEFKIDRASECRKKYAFKACHPKIKSFYFA 650
    ||||||||||||||||||||||||||||||||||||||||||||
601 ASLYWYINEEDEKAEGFISLPEFKIDRASECRKKYAFKACHPKIKSFYFA 650

651 AEHLDDMNRWLNRLNMLTAGYAERERIKQEQDYWSESDKEEADTPSTPKQ 700
    ||||||||||||||||||||||||||||||||||||||||||||
651 AEHLDDMNRWLNRLNMLTAGYAERERIKQEQDYWSESDKEEADTPSTPKQ 700

701 DSPPPPYDTPRPPSMSCASPYVEAKHSRLSSTETSQSQSSHEEFRQEV 750
    ||||||||||||||||||||||||||||||||||||||||||||
701 DSPPPPYDTPRPPSMSCASPYVEAKHSRLSSTETSQSQSSHEEFRQEV 750

751 GSSAVSPIRK TASQRRSWQDLIETPLTSSGLHYLQTLPLEDSVFSDSAAI 800
    ||||||||||||||||||||||||||||||||||||||||||||
751 GSSAVSPIRK TASQRRSWQDLIETPLTSSGLHYLQTLPLEDSVFSDSAAI 800

801 SPEHRRQSTLPTQKCHLQDHYGPYPLAESERMQVLNNGGKPRSFTLPRD 850
    ||||||||||||||||||||||||||||||||||||||||||||
801 SPEHRRQSTLPTQKCHLQDHYGPYPLAESERMQVLNNGGKPRSFTLPRD 850

851 SGFNHCCLNAPVSACDPQDDVQPPEVEEEEEEEEEEEGEAAGENIGEKS 898
    |||||||||||||||||:||||||||||||||| ||||||||
851 SGFNHCCLNAPVSACDPQDDIQPPEVEEEEEEEEE..EAAGENIGEKS 896

```

Fig. 11: SEQ ID NO. 3: nucleotide sequence of human MAGUIN-1 coding sequence

Length: 3105 bp

```

1 ATGGCTCTGA TAATGGAACC GGTGAGCAAA TGGTCTCCGA GTCAAGTAGT GGAAGTGGATG
61 AAAGGTCTTG ATGACTGTTT GCAGCAGTAT ATTAAGAAGT TTGAGAGGGA GAAGATCAGT
121 GGGGACCAGC TGCTGCGCAT TACACATCAG GAGCTAGAAG ATCTGGGGGT CAGCCGCATT
181 GGCCATCAGG AACTGATCTT GGAAGCAGTT GACCTTCTGT GTGCATTGAA TTATGGCTTG
241 GAAACAGAAA ATCTAAAAAC CCTTTCTCAC AAGTTGAATG CATCTGCCAA AAATCTGCAG
301 AATTTTATAA CAGGAAGGAG AAGGAGTGGC CATTATGATG GGAGGACCAG CCGAAAAATTG
361 CCAAACGACT TTCTGACCTC AGTTGTGGAT CTGATTGGAG CAGCCAAGAG TCTGCTTGCC
421 TGGTTGGACA GGTCAACCATT TGCTGCTGTG ACAGACTATT CAGTTACAAG AAATAATGTC
481 ATACAACTCT GCCTGGAGTT AACAACAATT GTGCAACAGG ATTGTACTGT ATATGAAACA
541 GAGAATAAAA TTCTTCACGT GTGTAAAACT CTTTCTGGAG TCTGTGACCA CATCATATCC
601 CTGTCGTGAG ATCCTCTGGT TTCACAGTCT GCTCACCTGG AAGTGATTCA ACTGGCAAAC
661 ATTAACACAA GCGAAGGGCT GGGTATGTAT ATTAATCTA CATATGATGG CCTCCATGTA
721 ATTACTGGAA CCACAGAAAA TTCACCTGCA GATCGGTGCA AGAAAAATCCA TGCTGGCGAT
781 GAAGTGATTG AAGTTAATCA TCAGACTGTG GTGGGGTGGC AGTTGAAAAA TTTGGTGAAT
841 GCACTACGAG AGGACCCGAG TGGTGTATC TTAACCTTGA AAAAGCGACC TCAGAGCATG
901 CTTACCTCAG CACCAGCTTT ACTGAAAAAT ATGAGATGGA AGCCCCTTGC TCTGCAGCCT
961 CTTATACCTA GAAGTCCAC AAGCAGCGTT GCCACGCCTT CCAGCACCAT CAGTACACCC
1021 ACCAAAGAG ACAGTTCTGC CCTCCAGGAT CTCTACATTC CCCCTCCTCC TGCAGAACCA
1081 TATATTCCCA GGGATGAAAA AGGAAACCTT CCTTGTGAAG ACCTCAGAGG ACATATGGTG
1141 GGCAAGCCAG TGATAAGGG ATCTGAATCA CCAAATTCAT TTCTGGATCA GGAATATCGA
1201 AAGAGATTTA ATATTGTGCA AGAAGATACT GTCTTATATT GCTATGAATA TGAAAAAGGA
1261 AGATCAAGTA GTCAAGGAAG ACGAGAAAGC ACCCAACTT ATGGCAAGCT ACGACCTATA
1321 TCTATGCCAG TGAATATAA TTGGGTGGGG GACTATGAAG ATCCAAATAA GATGAAGAGA
1381 GATAGTAGAA GAGAAAACCT TCTACTTCGG TATATGAGCA ATGAAAAGAT TGCTCAAGAA
1441 GAATACATGT TTCAGAGAAA CAGCAAAAAG GACACAGGGA AGAAGTCAA AAAGAAGGGT
1501 GATAAGAGTA ATAGCCCAAC TCACTATPCA TTGCTACCTA GTTTACAAAT GGATGCACTG
1561 AGACAAGACA TCATGGGCAC TCCTGTGCCA GAGACCACAC TATACCATAC ATTTAGCAG
1621 TCCTCACTGC AGCACAATC AAAGAAGAAA AACAAAGGTC CTATAGCAGG CAAGAGCAAA
1681 AGACGAATTT CTGCAAAGA TCTTGGCCGT GGTGACTGTG AGGGCTGGCT TTGAAAAAAG
1741 AAAGATGCGA AGAGTTACTT TTCACAGAAA TGGAAAAAAT ATTGGTTTGT CCTAAAGGAT
1801 GCATCCCTTT ATTGGTATAT TAATGAGGAG GATGAAAAAG CAGAAGGATT CATTAGCCTG
1861 CCTGAATTTA AAATTGATAG AGCCAGTGAA TGCCGCAAAA AATATGCATT CAAAGCCTGT
1921 CATCTAAAAA TCAAAAGCTT TTATTTTGCT GCTGAACATC TTGATGATAT GAACAGGTGG
1981 CTTAACAGAA TTAATATGCT GACTGCAGGA TATGCAGAAA GAGAGAGGAT TAAGCAGGAA
2041 CAAGATTACT GGAGTGAGAG TGACAAGGAA GAAGCAGATA CTCCATCAAC ACCAAAACAA
2101 GATAGCCCTC CACCCCATTA TGATACATAC CCACGACCTC CCTCGATGAG TTGCGCCAGT
2161 CCTTATGTGG AAGCAAAACA TAGCCGACTT TCCTCCACGG AGACTTCTCA GTCTCAGTCT
2221 TCTCATGAGG AGTTTCGCCA GGAAGTAACT GGGAGCAGTG CAGTGTCTCC CATTGCAAG
2281 ACAGCCAGTC AGCGCCGCTC CTGGCAGGAT TTAATTGAGA CGCCACTGAC AAGTTCAGGC
2341 TTACACTATC TTCAGACTCT GCCCCTGGAG GATTCTGTCT TCTCTGACTC CGCGGCCATC
2401 TCCCCAGAGC ACAGGCGGCA GTCTACCCTG CCAACTCAGA AATGCCACCT GCAGGATCAC
2461 TATGGGCCAT ACCCCTTAGC TGAGAGTGAG AGGATGCAAG TGCTAAATGG AAATGGGGGC
2521 AAGCCTCGAA GTTTTACTCT GCCTCGAGAT AGCGGGTTCA ACCATTGCTG TCTGAATGCT
2581 CCAGTTAGTG CCTGTGACCC ACAGGATGAC GTGCAACCCC CAGAGGTGGA GGAAGAGGAG
2641 GAGGAGGAGG AGGAGGAAGG GGAGGCAGCA GGGGAAAACA TAGGAGAAAA AAGTGAAAGC
2701 AGAGAAGAAA AGTTAGGAGA CTCATTGCAA GATTATACA GGGCACTGGA GCAGGCCAGT
2761 CTGTCACCCAC TAGGAGAACA TCGTATTTCA ACCAAGATGG AATACAAGCT ATCATTTATA
2821 AAAAGATGTA ATGATCCTGT AATGAATGAA AACTACACC GGCTGAGAAT TCTCAAAGC
2881 ACTTTAAAGG CCAGAGAAGG GGAAGTAGCC ATTATCGATA AAGTCCTAGA CAATCCAGAC
2941 TTGACATCTA AAGAATTCCA ACAATGGAAG CAGATGTACC TCGACCTTTT CTTGGATATC
3001 TGTCAAAATA CCACCTCAAA TGACCCACTG AGTATTTCTT CTGAAGTAGA TGTAATCACT
3061 TCCTCTCTAG CACACACTCA TTCATACATT GAAACGCATG TCTAA

```

Fig. 12: SEQ ID NO. 4: nucleotide sequence of human MAGUIN-2 coding sequence

Length: 2697 bp

```

1  ATGGCTCTGA TAATGGAACC GGTGAGCAAA TGGTCTCCGA GTCAAGTAGT
51  GGACTGGATG AAAGGTCTTG ATGACTGTTT GCAGCAGTAT ATTAAGAAGT
101 TTGAGAGGGA GAAGATCAGT GGGGACCAGC TGCTGCGCAT TACACATCAG
151 GAGCTAGAAG ATCTGGGGGT CAGCCGCATT GGCCATCAGG AACTGATCTT
201 GGAAGCAGTT GACCTTCTGT GTGCATTGAA TTATGGCTTG GAAACAGAAA
251 ATCTAAAAAC CCTTCTCAC AAGTTGAATG CATCTGCCAA AAATCTGCAG
301 AATTTTATAA CAGGAAGGAG AAGGAGTGGC CATTATGATG GGAGGACCAG
351 CCGAAAATTG CCAAACGACT TTCTGACCTC AGTTGTGGAT CTGATTGGAG
401 CAGCCAAGAG TCTGCTTGCC TGGTTGGACA GGTCAACCATT TGCTGCTGTG
451 ACAGACTATT CAGTTACAAG AAATAATGTC ATACAACCTC GCCTGGAGTT
501 AACACAATT GTGCAACAGG ATTGTACTGT ATATGAAACA GAGAATAAAA
551 TTCTTCACGT GTGTAAAACT CTTTCTGGAG TCTGTGACCA CATCATATCC
601 CTGTCGTCAG ATCCTCTGGT TTCACAGTCT GCTCACCTGG AAGTGATTCA
651 GCTGGCAAAC ATTAAACCAA GCGAAGGGCT GGGTATGTAT ATTAATCTA
701 CATATGATGG CCTCCATGTA ATTACTGGAA CCACAGAAAA TTCACCTGCA
751 GATCGGTGCA AGAAAATCCA TGCTGGCGAT GAAGTGATTG AAGTTAATCA
801 TCAGACTGTG GTGGGGTGGC AGTTGAAAAA TTTGGTGAAT GCACTACGAG
851 AGGACCCGAG TGGTGTTATC TTAACCTTGA AAAAGCGACC TCAGAGCATG
901 CTTACCTCAG CACCAGCTTT ACTGAAAAAT ATGAGATGGA AGCCCCCTTG
951 TCTGCAGCCT CTTATACCTA GAAGTCCAC AAGCAGCGTT GCCACGCCTT
1001 CCAGCACCAT CAGTACACCC ACCAAAAGAG ACAGTTCTGC CCTCCAGGAT
1051 CTCTACATTC CCCCTCCTCC TGCAGAACCA TATATTCCCA GGGATGAAAA
1101 AGGAAACCTT CCTTGTGAAG ACCTCAGAGG ACATATGGTG GGCAAGCCAG
1151 TGCATAAGGG ATCTGAATCA CCAAATTCAT TTCTGGATCA GGAATATCGA
1201 AAGAGATTTA ATATTGTGCA AGAAGATACT GTCTTATATT GCTATGAATA
1251 TGAAAAAGGA AGATCAAGTA GTCAAGGAAG ACGAGAAAGC ACCCCAAGTT
1301 ATGGCAAGCT ACGACCTATA TCTATGCCAG TGGAAATATA TTGGGTGGGG
1351 GACTATGAAG ATCCAAATAA GATGAAGAGA GATAGTAGAA GAGAAAAGTC
1401 TCTACTTCGG TATATGAGCA ATGAAAAGAT TGCTCAAGAA GAATACATGT
1451 TTCAGAGAAA CAGCAAAAAG GACACAGGGA AGAAGTCAAA AAAGAAGGGT
1501 GATAAGAGTA ATAGCCCAAC TCACTATTCA TTGCTACCTA GTTTACAAAT
1551 GGATGCACTG AGACAAGACA TCATGGGCAC TCCTGTGCCA GAGACCACAC
1601 TATACCATAC ATTTCAGCAG TCCTCACTGC AGCACAAATC AAAGAAGAAA
1651 AACAAAGGTC CTATAGCAGG CAAGAGCAAA AGACGAATTT CTGCAAAAGA
1701 TCTTGGCCGT GGTGACTGTG AGGGCTGGCT TTGGAAAAAG AAAGATGCGA
1751 AGAGTTACTT TTCACAGAAA TGGAAAAAAT ATTGGTTTGT CCTAAAGGAT
1801 GCATCCCTTT ATTGGTATAT TAATGAGGAG GATGAAAAAG CAGAAGGATT
1851 CATTAGCCTG CCTGAATTTA AAATTGATAG AGCCAGTGAA TGCCGCAAAA
1901 AATATGCATT CAAAGCCTGT CATCCTAAAA TCAAAAGCTT TTATTTTGCT
1951 GCTGAACATC TTGATGATAT GAACAGGTGG CTTAACAGAA TTAATATGCT
2001 GACTGCAGGA TATGCAGAAA GAGAGAGGAT TAAGCAGGAA CAAGATTACT
2051 GGAGTGAGAG TGACAAGGAA GAAGCAGATA CTCCATCAAC ACCAAAACAA
2101 GATAGCCCTC CACCCCATTA TGATACATAC CCACGACCTC CCTCGATGAG
2151 TTGCGCCAGT CCTTATGTGG AAGCAAAACA TAGCCGACTT TCCTCCACGG
2201 AGACTTCTCA GTCTCAGTCT TCTCATGAGG AGTTTCGCCA GGAAGTAACT
2251 GGGAGCAGTG CAGTGTCTCC CATTGCAAG ACAGCCAGTC AGCGCCGCTC
2301 CTGGCAGGAT TTAATTGAGA CGCCACTGAC AAGTTCAGGC TTACACTATC
2351 TTCAGACTCT GCCCCTGGAG GATTCTGTCT TCTCTGACTC CGCGGCCATC
2401 TCCCCAGAGC ACAGGCGGCA GTCTACCCTG CCAACTCAGA AATGCCACCT
2451 GCAGGATCAC TATGGGCCAT ACCCCTTAGC TGAGAGTGAG AGGATGCAAG
2501 TGCTAAATGG AAATGGGGGC AAGCCTCGAA GTTTTACTCT GCCTCGAGAT
2551 AGCGGGTTCA ACCATTGCTG TCTGAATGCT CCAGTTAGTG CCTGTGACCC
2601 ACAGGATGAC GTGCAACCCC CAGAGGTGGA GGAAGAGGAG GAGGAGGAGG
2651 AGGAGGAAGG GGAGGCAGCA GGGGAAAACA TAGGAGAAAA AAGCTAA

```

Fig. 13: SEQ ID NO. 5: nucleotide sequence of human MAGUIN-1 cDNA

Length: 5749 bp

```
1  CGGGCAGCTA  GTCGTGCTCG  GGGCTTCACT  CCCGCGCGTG  AGGCGAGCGG  GCAAGTTGGC
61  TGAGGGCGTG  CGGCAGAGGC  TGCTTCCCTC  GGCAGACGCA  CCCCTCAGCA  ACTCAAGCTA
121  TGAAGTGAAG  CTCCCTAGGG  ACGGAGACCG  GAGCGGAGCG  GCGGAGGCAG  CAGCAGCAGC
181  AGCAGCAGCA  GCAGCAGCAG  CAGCCGCCGC  CGCCGCCGCC  TTAGCGGGAA  CTGAGCAGAC
241  CCGGCGCGGA  GCCACGACTC  CTGCACGTTT  ACCTCCCTGT  CGCCGTTTCT  GCCGCGCGTT
301  GGCTAAAAGA  CGTTACAGCC  GCGAGACCCG  ACACACAAAA  GCCGCTTTCT  CCGCGCGGCC
361  CGCCAGGGA  GGCTGCGGCC  AGCAAGGGAC  CCCACCTGAG  AGCAGCTCGG  GCTGCTGAGT
421  TCGTTTTGTG  TCTGAGCTCT  GCGCTCTGCA  CGGAACCGAC  CCCGTACCCA  TGGCTCTGAT
481  AATGGAACCG  GTGAGCAAA  GGTCTCCGAG  TCAAGTAGTG  GACTGGATGA  AAGTCTTGA
541  TGAAGTTTG  CAGCAGTATA  TTAAGAACTT  TGAGAGGGAG  AAGATCAGTG  GGGACCAGCT
601  GCTGCGCATT  ACACATCAGG  AGCTAGAAGA  TCTGGGGGTC  AGCCGCATTG  GCCATCAGGA
661  ACTGATCTTG  GAAGCAGTTG  ACCTTCTGTG  TGCATTGAAT  TATGGCTTGG  AAACAGAAAA
721  TCTAAAAACC  CTTTCTCACA  AGTTGAATGC  ATCTGCCAAA  AATCTGCAGA  ATTTTATAAC
781  AGGAAGGAGA  AGGAGTGGCC  ATTATGATGG  GAGGACCAGC  CGAAAATTGC  CAAACGACTT
841  TCTGACCTCA  GTTGTGGATC  TGATTGGAGC  AGCCAAGAGT  CTGCTTGCC  GGTGGACAG
901  GTCACCATTT  GCTGCTGTGA  CAGACTATTC  AGTTACAAGA  AATAATGTCA  TACAACCTCTG
961  CCTGGAGTTA  ACAACAATTG  TGCAACAGGA  TTGTACTGTA  TATGAAACAG  AGAATAAAAT
1021  TCTTCACGTG  TGTAAGACTC  TTTCTGGAGT  CTGTGACCAC  ATCATATCCC  TGTGCTCAGA
1081  TCCTCTGGTT  TCACAGTCTG  CTCACCTGGA  AGTGATTCAA  CTGGCAAACA  TTAACCAAG
1141  CGAAGGGCTG  GGTATGTATA  TTAATCTAC  ATATGATGGC  CTCCATGTAA  TTACTGGAAC
1201  CACAGAAAAT  TCACCTGCAG  ATCGGTGCAA  GAAAATCCAT  GCTGGCGATG  AAGTGATTCA
1261  AGTTAATCAT  CAGACTGTGG  TGGGTGGCA  GTTGAAAAAT  TTGGTGAATG  CACTACGAGA
1321  GGACCCGAGT  GGTGTTATCT  TAACTTTGA  AAAGCGACCT  CAGAGCATGC  TTACCTCAGC
1381  ACCAGCTTTA  CTGAAAAATA  TGAGATGGAA  GCCCTTGCT  CTGCAGCCTC  TTATACCTAG
1441  AAGTCCCACA  AGCAGCGTTG  CCACGCCTTC  CAGCACCATC  AGTACACCA  CCAAAAGAGA
1501  CAGTTCTGCC  CTCCAGGATC  TCTACATTCC  CCCTCCTCCT  GCAGAACCAT  ATATTCCCAG
1561  GGATGAAAAA  GGAAACCTTC  CTTGTGAAGA  CCTCAGAGGA  CATATGGTGG  GCAAGCCAGT
1621  GCATAAGGGA  TCTGAATCAC  CAAATTCATT  TCTGGATCAG  GAATATCGAA  AGAGATTTAA
1681  TATTGTCGAA  GAAGATACTG  TCTTATATTG  CTATGAATAT  GAAAAAGGAA  GATCAAGTAG
1741  TCAAGGAAGA  CGAGAAAGCA  CCCCACCTTA  TGGCAAGCTA  CGACCTATAT  CTATGCCAGT
1801  GGAATATAAT  TGGGTGGGGG  ACTATGAAGA  TCCAAATAAG  ATGAAGAGAG  ATAGTAGAAG
1861  AGAAAACTCT  CTACTTCGGT  ATATGAGCAA  TGAAAAGATT  GCTCAAGAAG  AATACATGTT
1921  TCAGAGAAAC  AGCAAAAAGG  ACACAGGGAA  GAAGTCAAAA  AAGAAGGGTG  ATAAGAGTAA
1981  TAGCCCAACT  CACTATTTCAT  TGCTACCTAG  TTTACAAATG  GATGCACTGA  GACAAGACAT
2041  CATGGGCACT  CCTGTGCCAG  AGACCACACT  ATACCATA  TTTACAGCAGT  CCTCACTGCA
2101  GCACAAATCA  AAGAAGAAAA  ACAAGGTCC  TATAGCAGGC  AAGAGCAAAA  GACGAATTTT
2161  TTGCAAAGAT  CTTGGCCGTG  GTGACTGTGA  GGGCTGGCTT  TGGAAAAAGA  AAGATGCGAA
2221  GAGTTACTTT  TCACAGAAAT  GGAAAAATA  TTGGTTTGTC  CTAAGGATG  CATCCCTTTA
2281  TTGGTATATT  AATGAGGAG  ATGAAAAAGC  AGAAGGATT  ATTAGCCTGC  CTGAATTTAA
2341  AATTGATAGA  GCCAGTGAAT  GCCGAAAAA  ATATGCATT  AAAGCCTGTC  ATCCTAAAT
2401  CAAAAGCTTT  TATTTTGCTG  CTGAACATCT  TGATGATATG  AACAGGTGGC  TTAACAGAAT
2461  TAATATGCTG  ACTGCAGGAT  ATGCAGAAAG  AGAGAGGATT  AAGCAGGAAC  AAGATTACTG
2521  GAGTGAGAGT  GACAAGGAAG  AAGCAGATAC  TCCATCAACA  CCAAAACAAG  ATAGCCCTCC
2581  ACCCCCATAT  GATACATACC  CACGACCTCC  CTCGATGAGT  TGCGCCAGTC  CTTATGTGGA
2641  AGTAAACAT  AGCCGACTTT  CCTCCACGGA  GACTTCTCAG  TCTCAGTCTT  CTCATGAGGA
2701  GTTTCGCCAG  GAAGTAAGTG  GGAGCAGTGC  AGTGTCTCCC  ATTCGCAAGA  CAGCCAGTCA
2761  GCGCCGCTCC  TGGCAGGATT  TAATTGAGAC  GCCACTGACA  AGTTCAGGCT  TACACTATCT
2821  TCAGACTCTG  CCCCTGGAGG  ATTCTGTCTT  CTCTGACTCC  GCGGCCATCT  CCCAGAGCA
```



```

2881 CAGGCGGCAG TCTACCCTGC CAACTCAGAA ATGCCACCTG CAGGATCACT ATGGGCCATA
2941 CCCCTTAGCT GAGAGTGAGA GGATGCAAGT GCTAAATGGA AATGGGGGCA AGCCTCGAAG

3001 TTTTACTCTG CCTCGAGATA GCGGGTTCAA CCATTGCTGT CTGAATGCTC CAGTTAGTGC
3061 CTGTGACCCA CAGGATGACG TGCAACCCCC AGAGGTGGAG GAAGAGGAGG AGGAGGAGGA
3121 GGAGGAAGGG GAGGCAGCAG GGGAAAACAT AGGAGAAAAA AGTGAAAGCA GAGAAGAAAA
3181 GTTAGGAGAC TCATTGCAAG ATTTATACAG GGCACCTGGAG CAGGCCAGTC TGTCAACCCT
3241 AGGAGAACAT CGTATTTCAA CCAAGATGGA ATACAAGCTA TCATTTATAA AAAAGATGTAA
3301 TGATCCTGTA ATGAATGAAA AACTACACCG GCTGAGAATT CTCAAAAGCA CTTTAAAGGC
3361 CAGAGAAGGG GAAGTAGCCA TTATCGATAA AGTCCTAGAC AATCCAGACT TGACATCTAA
3421 AGAATTCCAA CAATGGAAGC AGATGTACCT CGACCTTTTC TTGGATATCT GTCAAAATAC
3481 CACCTCAAAT GACCCACTGA GTATTTCTTC TGAAGTAGAT GTAATCACTT CCTCTCTAGC
3541 ACACACTCAT TCATACATTG AAACGCATGT CTAAATGTAT TCTGCCTTCA GACCATCTAG
3601 TACCTGCTGG TACTCTGAAC AAGTATATAA GGTAGTTTTT ATATCAATGT GTGGAACACT
3661 TGACAAGCTA TACTTTAATG TTACCAAACCT ATATGAAACA AACCATATAT GGTCAACAATA
3721 CCACTATCTT TAATGAGCAT TTGTATATTT TATATGCAAC AGTGCTCAGC TTATGTTTAC
3781 CATGTGCAAA ATCAACTGTC TTTAATGACT TAAAATTAAC TTTTGCAAAAC AATTCTAAAT
3841 ACAGGTGGTC TTCAAGTAGT AAAACCACAA AAGGCAGTTT TCTATCTATG GTCATCTTTT
3901 CTCCCTTTAA GTTAATTTTA TATAACAAG ACTTCAAAAG TAAATCACAT TTTTTCAGGT
3961 GCAGACATCC TTGTGGGTGG GAAAGAATTT AAACCTTTTT TATATTTATT AAAATGTTCT
4021 AAGAATTTTC TTAAACATTG CACAAAGTTT AATGCTGTAG TTTTATTTTT GTGAAATGTA
4081 GATGCGCATA CAAGAGCTAA GCAAAATAGA AGAGCATCGA CATAAGAAAA GTTCAGGTAT
4141 CTAATATTCC TCTTAATAGT CTATTAACCT GTGAAAGCTA AGTTAATGGA AATATTATTC
4201 CAAATCTATG AGAACACTTG GTGTATCAGG GCAAAGCTTT GTAAGATGTT TTTGTAACATA
4261 AGACCAAAAAT TGAAGATAGA GCTGCTTTAT TTTCTGGTT TAAATCTTCC TTTATTTTTG
4321 TAGTGATGAG ATGCTGATTG TGTACAGAAG AATTTGAGAG GGGATTTTTTA AAAACGACT
4381 TAACACACCC AGAAAGGCAG CTAACAGCTA TATATATATA TAAATTTTCA CCCAAACTCA
4441 TGTTTTTAAA CTCCAACCTC TAAAAGACAA CAAGGTATAA ACTGAAATGA ATCAACTTTC
4501 CACTTAGTTT CCAATTTTCC CCTAGTCCAC TAATTAACT TAGGTAATTA TACTTCAGGT
4561 AGGGAAGTAC AATATGTTTA GTTTCAGGCT GATGTGTGTT ATAAAAACA ACACTGAAAA
4621 ATAAAAATGT ACTTCCCTTC TAAGGAGCAA GCAGGTGATG GTCATTCAAA GAGATGTCAC
4681 ATTGAATTAT GAGAGAAACA ATTTAGAGGT TTTTTCCTG GCTTCATGAA TTGTTCTATA
4741 GAGTGGATGA AGTCTAAGGA AAAGTCCTCT TCATATATTT CCATTTATAA GCGTCTTGTT
4801 TTTGAAAGTG ATCACAGCAT GAAAATGACT GTGCTGCTTT TTAGTGCTG GCTGCATAAT
4861 GTACAAGTCA CAATTTGCTG TTTTTTTCAG GAGGAGAAAG GGAACCTCCT TTACTATTCT
4921 ATATCCTAAA ATCTACTTCT AATCAGCTTT ATACTGTTGC CTGTACAGCT CAGTGAATGT
4981 ACTTTCATCT TTAAGAGTTC AGATATATGC CAGTGAATAT TTTTGCTGTA GAGGAGAAAG
5041 TAAAAACTCC ACAGCGGGGA TCTTTTCTT TGCTTTTGAA ACCACCATTG AATCACTATC
5101 GTTTTGCAGA CTTTGCACAA CTGTACAGGA GAGTGGCCTT TCTACAGCAC ATTTTCAGTA
5161 ATCCTATATT TAGTCAAAAT GGATGAGAAA TCATGTATTA ATGTTTGTAT GGAATTTTGG
5221 GTCCAGTGTA ATATTTTTAT CATTTAAAAA GAACTCTATT TGTA AAAACA TTTATTTACT
5281 GCATGGATAT TGACGCACAT TAAATTTGTG GGATTTTGTA TATGTAAAAA AAAAAAAA
5341 AAAAAAAAC AAAAAACCTC TTGCTCTAAA ATGAAGTGTG CTTGTTAACA GGTGTTTAGA
5401 CTTATTGATG TTTACTAGAC CAAATGTGTA TGTTCACTTA AAAATATATG TACCTGATGG
5461 ATGTGTCATG TTTACAGTGG CCAGGTTGTG GCCTGTAAAC AGCAAGCAGT TGACGGGAAG
5521 ACTAGCTCTG TTGCTACTAA GCAGCTTTTA CTTTGTGAAA GTCAGCTCTG TTGTTTTAAA
5581 TGGTAAAAAT TAACTAATG AATTTGACAA GACTCGTGGC TAGCCTAGCA TGAAAGAGAC
5641 CTTTTAACAC TATATAATAT CTGTACATTT TATTGCATTC GTTTCAAATC TAGGAGAGAG
5701 GCAGCACTGT AAAGTGAAGT CAAATAAATT CAGCTCTTAA TGAATCCTT

```

Fig. 14: SEQ ID NO. 6: nucleotide sequence of human MAGUIN-2 cDNA**Length: 4350 bp**

```
1  GTGCTCGGGG CTTCACTCCC GCGCGTGAGG CGAGCGGGCA AGTTGGCTGA
51  GGGCGTGCGG CAGAGGCTGC TTCCCTCGGC GACGCGACCC CTCAGCAACT
101 CAAGCTATGA ACTGAAGCTC CCTAGGGACG GAGACCGGAG CGGAGCGGGC
151 GAGGCAGCAG CAGCAGCAGC AGCAGCAGCA GCAGCAGCAG CCGCCGCCGC
201 CGCCGCCTTA GCGGGAAGTG AGCAGACCCG GCGCGGAGCC ACGACTCCTG
251 CACGTTTACC TCCCTGTCGC CGTTCCTGCC GCGCGTTGGC TAAAAGACGT
301 TACAGCCGCG AGACCCGACA CACAAAAGCC GCTTTCTCCG CGCCGCCCGC
351 CCAGGGAGGC TCGGGCCAGC AAGGGACCCC ACCTGAGAGC AGCTCGGGCT
401 GCTGAGTTCG TTTTGTGTCT GAGCTCTGCG CTCTGCACGG AACCGACCCC
451 GTACCCATGG CTCTGATAAT GGAACCGGTG AGCAAATGGT CTCCGAGTCA
501 AGTAGTGGAC TGGATGAAAG GTCTTGATGA CTGTTTGAGC CAGTATATTA
551 AGAACTTTGA GAGGGAGAAG ATCAGTGGGG ACCAGCTGCT GCGCATTACA
601 CATCAGGAGC TAGAAGATCT GGGGGTCAGC CGCATTGGCC ATCAGGAACT
651 GATCTTGGAA GCAGTTGACC TTCTGTGTGC ATTGAATTAT GGCTTGGAAA
701 CAGAAAATCT AAAAACCCCT TCTCACAAGT TGAATGCATC TGCCAAAAAT
751 CTGCAGAATT TTATAACAGG AAGGAGAAGG AGTGGCCATT ATGATGGGAG
801 GACCAGCCGA AAATTGCCAA ACGACTTTCT GACCTCAGTT GTGGATCTGA
851 TTGGAGCAGC CAAGAGTCTG CTTGCCTGGT TGGACAGGTC ACCATTGCT
901 GCTGTGACAG ACTATTCACT TACAAGAAAT AATGTCATAC AACTCTGCCT
951 GGAGTTAACA ACAATTGTGC AACAGGATTG TACTGTATAT GAAACAGAGA
1001 ATAAAAATTCT TCACGTGTGT AAAACTCTTT CTGGAGTCTG TGACCACATC
1051 ATATCCCTGT CGTCAGATCC TCTGGTTTCA CAGTCTGCTC ACCTGGAAGT
1101 GATTCAGCTG GCAAACATTA AACCAAGCGA AGGGCTGGGT ATGTATATTA
1151 AATCTACATA TGATGGCCTC CATGTAATTA CTGGAACCAC AGAAAAATTCA
1201 CCTGCAGATC GGTGCAAGAA AATCCATGCT GGCGATGAAG TGATTCAAGT
1251 TAATCATCAG ACTGTGGTGG GGTGGCAGTT GAAAAATTG GTGAATGCAC
1301 TACGAGAGGA CCCGAGTGGT GTTATCTTAA CTTTGAAAAA GCGACCTCAG
1351 AGCATGCTTA CCTCAGCACC AGCTTTACTG AAAAATATGA GATGGAAGCC
1401 CCTTGCTCTG CAGCCTCTTA TACCTAGAAG TCCCACAAGC AGCGTTGCCA
1451 CGCCTTCCAG CACCATCAGT ACACCCACCA AAAGAGACAG TTCTGCCCTC
1501 CAGGATCTCT ACATTCCCC TCCTCCTGCA GAACCATATA TTCCCAGGGA
1551 TGAAAAAGGA AACCTTCCTT GTGAAGACCT CAGAGGACAT ATGGTGGGCA
1601 AGCCAGTGCA TAAGGGATCT GAATCACCAA ATTCATTCTT GGATCAGGAA
1651 TATCGAAAGA GATTTAATAT TGTCGAAGAA GATACTGTCT TATATTGCTA
1701 TGAATATGAA AAAGGAAGAT CAAGTAGTCA AGGAAGACGA GAAAGCACCC
1751 CAACTTATGG CAAGCTACGA CCTATATCTA TGCCAGTGGA ATATAATTGG
1801 GTGGGGGACT ATGAAGATCC AAATAAGATG AAGAGAGATA GTAGAAGAGA
1851 AAATCTCTTA CTTCGGTATA TGAGCAATGA AAAGATTGCT CAAGAAGAAT
1901 ACATGTTTCA GAGAAACAGC AAAAAGGACA CAGGGAAGAA GTCAAAAAAG
1951 AAGGGTGATA AGAGTAATAG CCCAACTCAC TATTCATTGC TACCTAGTTT
2001 ACAAATGGAT GCACTGAGAC AAGACATCAT GGGCACTCCT GTGCCAGAGA
2051 CCACACTATA CCATACATT CAGCAGTCCT CACTGCAGCA CAAATCAAAG
2101 AAGAAAAACA AAGTCTCTAT AGCAGGCAAG AGCAAAAGAC GAATTCTTGG
2151 CAAAGATCTT GGCCGTGGTG ACTGTGAGGG CTGGCTTTGG AAAAAGAAAG
2201 ATGCGAAGAG TTACTTTTCA CAGAAATGGA AAAAATATTG GTTTGTCTTA
2251 AAGGATGCAT CCCTTTATTG GTATATTAAT GAGGAGGATG AAAAAGCAGA
```

2301	AGGATTCATT	AGCCTGCCTG	AATTTAAAAAT	TGATAGAGCC	AGTGAATGCC
2351	GCAAAAAATA	TGCATTCAAA	GCCTGTCATC	CTAAAATCAA	AAGCTTTTAT
2401	TTTGCTGCTG	AACATCTTGA	TGATATGAAC	AGGTGGCTTA	ACAGAATTAA
2451	TATGCTGACT	GCAGGATATG	CAGAAAGAGA	GAGGATTAAG	CAGGAACAAG
2501	ATTACTGGAG	TGAGAGTGAC	AAGGAAGAAG	CAGATACTCC	ATCAACACCA
2551	AAACAAGATA	GCCCTCCACC	CCCATATGAT	ACATACCCAC	GACCTCCCTC
2601	GATGAGTTGC	GCCAGTCCTT	ATGTGGAAGC	AAAACATAGC	CGACTTTCCT
2651	CCACGGAGAC	TTCTCAGTCT	CAGTCTTCTC	ATGAGGAGTT	TCGCCAGGAA
2701	GTAAGTGGGA	GCAGTGCAGT	GTCTCCCATT	CGCAAGACAG	CCAGTCAGCG
2751	CCGCTCCTGG	CAGGATTTAA	TTGAGACGCC	ACTGACAAGT	TCAGGCTTAC
2801	ACTATCTTCA	GACTCTGCCC	CTGGAGGATT	CTGTCTTCTC	TGACTCCGCG
2851	GCCATCTCCC	CAGAGCACAG	GCGGCAGTCT	ACCCTGCCAA	CTCAGAAATG
2901	CCACCTGCAG	GATCACTATG	GGCCATACCC	CTTAGCTGAG	AGTGAGAGGA
2951	TGCAAGTGCT	AAATGGAAAT	GGGGGCAAGC	CTCGAAGTTT	TACTCTGCCT
3001	CGAGATAGCG	GGTTCAACCA	TTGCTGTCTG	AaTGCTCCAG	TTAGTGCCTG
3051	TGACCCACAG	GATGACGTGC	AACCCCCAGA	GGTGGAGGAA	GAGGAGGAGG
3101	AGGAGGAGGA	GGAAGGGGAG	GCAGCAGGGG	AAAACATAGG	AGAAAAAGC
3151	TAATACACTG	CGAGAGTTGG	TAGAACCTCT	CCATGCCAAA	TCGGATCCAC
3201	TTCTGTTTGGC	ACTCAACCCA	TTGGAATCAC	AGATTGATAA	GCTAATGTTT
3251	AGAGAATTTA	GATCGGAGAG	AGTCGGTACG	GCGCAGACTC	AACATCAACC
3301	TCTTGCAAGC	AACATAAATG	GCCTCGTCCCT	TGCTGTTTAT	AACAGAAAAC
3351	AGACTTGTA	AAAGCTTAGA	TCATCAAGTG	TTTTGGATTG	GGGGCCTCCC
3401	AAAGGGATAT	AAGAGGGGCA	GGCCACTCTT	AAGAAGAATG	CGAGCTTTCT
3451	ACATTGGGAC	TAGCATAAGA	TCAAAGCCAA	TCAAGATGGA	GCACAGTAAC
3501	AGAAAACTGC	GGTTTCTGTG	GGAGAACAGA	AGGGGAAAGG	GTCTTAACTG
3551	GGAAAGGGCT	CTGTGTGGTA	ACACCTCAGT	TGTGTTCTCC	TGACACCAGG
3601	AAAAGAGAGG	GATCAGCTTC	AATAACTAGA	AAATTCTGGC	TGTTTAATGG
3651	ACTCTTTGGT	GGCCTCTTTA	AGGCAAAGCA	GAGAAAGCAA	ATTATGTATT
3701	AAGTGTATTT	TGCATTTTTA	AAACTTGACG	TGCTGTATTG	TACTAAATTA
3751	AGTGTAATCT	ATTAAGGCAA	GGTATACACA	ATTTGCTTTG	AAACTTACTA
3801	TGTTTATTCT	ATTATAAAGT	GTATTCAGGT	GCAACACAGA	GACTGCTTTC
3851	GGTGACATTA	ATGAAGAAAA	TTTCTCATGC	CAGGCTTTAT	TATAGAATCT
3901	TCAGCTAAAA	TCCTAACTTT	CTCCTTATTT	CTTGGCACTT	GTATACAAGT
3951	GGTGTGCTT	CTTAGGGCAG	GCATGAGCTA	TTCTTTTCTG	TAAAATATTT
4001	TGAATCTATA	GGCTGTGGGT	TTCATTTTGT	AAAAGTATTT	TGTCTGGATG
4051	TCTTTCAAAC	TAGCTTCAGA	TATTATTTAA	TACTATGTAA	CTGGGTCCCC
4101	TATGGCTCAA	TCAATATTGC	TTATTTTCTT	TCTGTAGTGG	ATGTGAAATT
4151	TCCTTTAGTT	GGATAAGATA	CACTGTAATA	ATTTTAATGC	TAATTAATGA
4201	TATTTTCATAC	TGTGCAATGA	ACAGATAATT	TAACACTGTA	TTTTGAAATG
4251	TTTTTTTCTT	CCTGTCACCG	CAGTGTGTGG	TATTGCATAA	TGTGAATACC
4301	TGTA AAAATA	TAAATTACTT	AAAAATAAAA	ATATGACCAA	TTGGTATCAG

Figure 15: SEQ ID NO. 7

Length: 50 bp

1 GGAGAGAGGCAGCACTGTAAACTGAAGTCAAATAAATTCAGCTCTTAATG

**Fig. 16: Alignment of SEQ ID NO. 7
with human MAGUIN-1 cDNA**

Length: 50 bp

```
1 GGAGAGAGGCAGCACTGTAACTGAAGTCAAATAAATTCAGCTCTTAATG 50
  |||
5693 GGAGAGAGGCAGCACTGTAACTGAAGTCAAATAAATTCAGCTCTTAATG 5742
```


**Fig. 18: Images of the human cerebral cortex
labeled with anti-Maguin-1 antiserum
and with DAPI**




Table 1:

sample	Δ (fold) (frontal / temporal cortex)
patient P012	2.46
patient P016	2.78
patient P010	4.14
patient P011	2.20
patient P014	1.48
patient P017	1.42
patient P019	1.68
control C011	1.28
control C012	1.29
control C014	0.30
control C005	1.36
control C008	1.15

Table 2:

sample	Δ (fold) (frontal cortex / hippocampus)
<hr/>	
patient P012	1.37
patient P016	3.07
patient P010	2.99
patient P011	2.28
patient P014	1.21
patient P019	1.48
 control C005	 1.74
control C008	0.39
control C004	0.87

Table 3:

sample	Δ (fold) (frontal / temporal cortex)
patient P012	2.68
patient P016	2.72
patient P010	11.73
patient P011	2.44
patient P014	1.77
patient P017	3.43
patient P019	4.02
control C011	1.42
control C012	1.22
control C014	0.30
control C005	0.92
control C008	0.81

Table 4:

sample	Δ (fold) (frontal cortex / hippocampus)
patient P012	1.57
patient P016	4.38
patient P010	9.08
patient P011	4.53
patient P014	0.72
patient P019	1.37
control C005	1.84
control C008	0.46
control C004	1.69

DIAGNOSTIC AND THERAPEUTIC USE OF HUMAN MAGUIN PROTEINS AND NUCLEIC ACIDS FOR NEURODEGENERATIVE DISEASES

[0001] The present invention relates to methods of diagnosing, prognosticating and monitoring the progression of neurodegenerative diseases in a subject. Furthermore, methods of therapy control and screening for modulating agents of neurodegenerative diseases are provided. The invention also discloses pharmaceutical compositions, kits, and recombinant animal models.

[0002] Neurodegenerative diseases, in particular Alzheimer's disease (AD), have a strongly debilitating impact on a patient's life. Furthermore, these diseases constitute an enormous health, social, and economic burden. AD is the most common neurodegenerative disease, accounting for about 70% of all dementia cases, and it is probably the most devastating age-related neurodegenerative condition affecting about 10% of the population over 65 years of age and up to 45% over age 85 (for a recent review see Vickers et al., *Progress in Neurobiology* 2000, 60: 139-165). Presently, this amounts to an estimated 12 million cases in the US, Europe, and Japan. This situation will inevitably worsen with the demographic increase in the number of old people ("aging of the baby boomers") in developed countries. The neuropathological hallmarks that occur in the brains of individuals with AD are senile plaques, composed of amyloid- β protein, and profound cytoskeletal changes coinciding with the appearance of abnormal filamentous structures and the formation of neurofibrillary tangles.

[0003] The amyloid- β (A β) protein evolves from the cleavage of the amyloid precursor protein (APP) by different kinds of proteases. The cleavage by the β / γ -secretase leads to the formation of A β peptides of different lengths, typically a short more soluble and slow aggregating peptide consisting of 40 amino acids and a longer 42 amino acid peptide, which rapidly aggregates outside the cells, forming the characteristic amyloid plaques (Selkoe, *Physiological Rev* 2001, 81: 741-66; Greenfield et al., *Frontiers Bioscience* 2000, 5: D72-83). Two types of plaques, diffuse plaques and neuritic plaques, can be detected in the brain of AD patients, the latter ones being the classical, most prevalent type. They are primarily found in the cerebral cortex and hippocampus. The neuritic plaques have a diameter of 50 μ m to 200 μ m and are composed of insoluble fibrillar amyloids, fragments of dead neurons, of microglia and astrocytes, and other components such as neurotransmitters, apolipoprotein E, glycosaminoglycans, α 1-antichymotrypsin and others. The generation of toxic A β deposits in the brain starts very early in the course of AD, and it is discussed to be a key player for the subsequent destructive processes leading to AD pathology. The other pathological hallmarks of AD are neurofibrillary tangles (NFTs) and abnormal neurites, described as neuropil threads (Braak and Braak, *Acta Neuropathol* 1991, 82: 239-259). NFTs emerge inside neurons and consist of chemically altered tau, which forms paired helical filaments twisted around each other. Along the formation of NFTs, a loss of neurons can be observed. It is discussed that said neuron loss may be due to a damaged microtubule-associated transport system (Johnson and Jenkins, *J Alzheimers Dis* 1996, 1: 38-58; Johnson and (1) Hartigan, *J Alzheimers Dis* 1999, 1: 329-351). The appearance of neurofibrillary tangles and their increasing number

correlates well with the clinical severity of AD (Schmitt et al., *Neurology* 2000, 55: 370-376).

[0004] AD is a progressive disease that is associated with early deficits in memory formation and ultimately leads to the complete erosion of higher cognitive function. The cognitive disturbances include among other things memory impairment, aphasia, agnosia and the loss of executive functioning. A characteristic feature of the pathogenesis of AD is the selective vulnerability of particular brain regions and subpopulations of nerve cells to the degenerative process. Specifically, the temporal lobe region and the hippocampus are affected early and more severely during the progression of the disease. On the other hand, neurons within the frontal cortex, occipital cortex, and the cerebellum remain largely intact and are protected from neurodegeneration (Terry et al., *Annals of Neurology* 1981, 10: 184-92).

[0005] The age of onset of AD may vary within a range of 50 years, with early-onset AD occurring in people younger than 65 years of age, and late-onset of AD occurring in those older than 65 years. About 10% of all AD cases suffer from early-onset AD, with only 1-2% being familial, inherited cases.

[0006] Currently, there is no cure for AD, nor is there an effective treatment to halt the progression of AD or even to diagnose AD ante-mortem with high probability. Several risk factors have been identified that predispose an individual to develop AD, among them most prominently the epsilon 4 allele of the three different existing alleles (epsilon 2, 3, and 4) of the apolipoprotein E gene (ApoE) (Strittmatter et al., *Proc Natl Acad Sci USA* 1993, 90: 1977-81; Roses, *Ann NY Acad Sci* 1998, 855: 738-43). The polymorphic plasmaprotein ApoE plays a role in the intercellular cholesterol and phospholipid transport by binding low-density lipoprotein receptors, and it seems to play a role in neurite growth and regeneration. Efforts to detect further susceptibility genes and disease-linked polymorphisms, lead to the assumption that specific regions and genes on human chromosomes 10 and 12 may be associated with late-onset AD (Myers et al., *Science* 2000, 290: 2304-5; Bertram et al., *Science* 2000, 290: 2303; Scott et al., *Am J Hum Genet* 2000, 66: 922-32).

[0007] Although there are rare examples of early-onset AD which have been attributed to genetic defects in the genes for amyloid precursor protein (APP) on chromosome 21, presenilin-1 on chromosome 14, and presenilin-2 on chromosome 1, the prevalent form of late-onset sporadic AD is of hitherto unknown etiologic origin. The mutations found to date account for only half of the familial AD cases, which is less than 2% of all AD patients. The late onset and complex pathogenesis of neurodegenerative disorders pose a formidable challenge to the development of therapeutic and diagnostic agents. It is pivotal to expand the pool of potential drug targets and diagnostic markers. It is therefore an object of the present invention to provide insight into the pathogenesis of neurological diseases and to provide methods, materials, agents, compositions, and animal models which are suited inter alia for the diagnosis and development of a treatment of these diseases. This object has been solved by the features of the independent claims. The subclaims define preferred embodiments of the present invention.

[0008] Neurons conduct signals in the form of electrical impulses. The communication between the cells of a neu-

ronal network involves several chemical steps, including the production, release, and transport of signal molecules and the recognition of such messengers by a receptor. These steps take place at the anatomical contact of an axon with the dendrites (axonodendritic), the cell body (axonosomatic), or rarely with the axon of another neuron, and also between neurons and cells of muscle- and gland tissue. Trillions of such specialized cell junctions (synapses) in the human brain are crucial for controlling mental activity and learning processes (Tessier-Lavigne and Goodman, *Science* 1996, 274: 1123-1133). A synapse is composed of the presynaptic element, the synaptic cleft with a spacing distance of about 20-30 nm and the postsynaptic component. They are responsible for altering the membrane potential of the postsynaptic neuron or other effector cells. The quality and intensity of information transferred relies on the number, location, and distribution of synapses. The basis of learning and memory is believed to be due to brain plasticity, i.e. to the plasticity of synapses. The storage and processing of information cause alterations in the structure, chemistry, and strength of synapses and the formation of new synapses (Poirazi and Mel, *Neuron* 2001, 29: 779-796). The postsynaptic density (PSD) is a specialized synaptic signaling assemblage, composed of a specific set of proteins which are assembled together and linked to the cytoplasmic face of the postsynaptic membrane. An important function of the postsynaptic density is the provision of a structural matrix consisting of cytoskeletal and regulatory proteins which localize and accumulate neurotransmitter receptors (e.g. glutamate receptors) and anchor signaling molecules at the postsynaptic membrane (Sheng and Kim, *Current Opinion Neurobiology* 1996, 6: 602-608). Neurotransmitter receptors convert the extracellular chemical signals into intracellular signals. Neurotransmitters are released from the presynaptic membrane into the synaptic cleft via exocytotic processes (vesicle formation). At the postsynaptic membrane they are bound by their specific receptors, resulting in the generation of second messengers. Thus, neurotransmitters function as mediators of nerve impulse transmission across the synapse. The PSD organizes and regulates postsynaptic signal transduction (Kim and Huganir, *Current Opinion Cell Biology* 1999, 11:248-254). To date, several components of the PSD have been identified, among them the prototypic synaptic scaffolding protein postsynaptic density (PSD)-95/synapse-associated protein (SAP) 90. PSD-95/SAP90 and its isoforms belong to a family of membrane-associated guanylate kinases (MAGUK) (Hirao et al., *Journal of Biological Chemistry* 1998, 273: 21105-21110; Hirao et al., *Journal of Biological Chemistry* 2000, 275: 2966-2972). The members of the MAGUK protein family are multiple PDZ-domain containing proteins which interact with many neuronal adhesion proteins, receptors (e.g. N-methyl-D-aspartate (NMDA)) and ion-channels (e.g. potassium channels) through these domains and mediate their assembling at the PSD (Kim et al., *Neuron* 1996, 17: 103-113).

[0009] In this context, a novel neuronal membrane-associated guanylate kinase-interacting protein, denoted MAGUIN, was found by Yao et al. (*Journal of Biological Chemistry* 1999, 274: 11889-11896). Using the PDZ-domain sequence of the neurospecific synaptic scaffolding molecule (S-SCAM) as bait, the authors screened a rat brain yeast two-hybrid library and obtained several positive clones, among them two clones subsequently named rat MAGUIN-1 and rat MAGUIN-2 (GenBank accession num-

bers AF102853 and AF102854, respectively). A Northern blot analysis of different rat tissues with a rat MAGUIN-1 probe revealed brain specific hybridization signals at 4.4 kDa and 5.4 kDa. MAGUIN proteins have a chimerical molecular structure consisting of several protein modules, an N-terminally located sterile alpha-motif (SAM) (aa 8-75), a PDZ-domain (aa 156-296) and a C-terminally located Pleckstrin-homology (PH)-domain (aa 571-667). The Sterile Alpha Motif (SAM) contains four different domain structures, spanning approximately 70 amino acids generating a compact five-helix bundle with a highly conserved hydrophobic core. This motif was found to be part of a number of types of proteins, including signal transduction proteins, playing a role in mediating protein-protein interactions or DNA binding (Schultz et al., *Protein Science* 1997, 6: 249-253). The term PDZ is named after three proteins (i.e. PSD-95/SAP90, *Drosophila discs-large tumor suppressor protein (Dlg-A)* and the tight junction protein ZO-1), originally identified as proteins sharing the same repeats of about 90 amino acids. These amino acids form a distinctive structure of two α helices and six β sheets which mediate the interaction with the carboxyl termini of various proteins. Often, PDZ-domains of different proteins can heterodimerize with each other. The target proteins are transmembrane receptors, ion channels, or signaling proteins. PDZ-domain binding seems to be important in receptor clustering and in recruiting signal transduction molecules to the plasma membrane. PDZ-domain harboring proteins are for example tyrosine phosphatases and the previously described membrane-associated guanylate kinase-like proteins (Doyle et al., *Cell* 1996, 85: 1067-1076). The Pleckstrin-homology (PH)-domain forms an anti-parallel perpendicular β -sheet sandwich with a succeeding α -helical structure. The β -sheet-loops are important for high affinity binding to specific phosphatidylinositol phosphates, allowing signaling proteins containing the PH-domain to anchor to membranes, for example as studied for GTP binding proteins, protein kinases and phospholipase C isoforms (Lemmon et al., *Trends Cell Biology* 1997, 7: 237-242).

[0010] Rat MAGUIN-1 and rat MAGUIN-2 cover 3099 and 2691 nucleotides of coding sequence, respectively, (GenBank accession numbers AF102853, AF102854) which encode for proteins of 1032 aa amino acids (rat MAGUIN-1) (GenBank accession number aad04568) and 896 amino acids (rat MAGUIN-2) (GenBank accession number aad04567), respectively. Rat MAGUIN-2 lacks the 3' terminal PDZ binding motif of rat MAGUIN-1. In neurons, the rat MAGUIN proteins are localized in the cell body and in neurites where they are associated with the plasma-membrane via their PH-domains. Full-length rat MAGUIN-1 could be recovered from neuronal membrane fractions. Rat MAGUIN-1, but not rat MAGUIN-2, interacts via the PDZ-binding motif with the PDZ-domain of PSD-95/SAP90 and the synaptic scaffolding molecule (S-SCAM) (Hirao et al., *Journal of Biological Chemistry* 1998, 273: 21105-21110). S-SCAM has recently been identified as a multiple PDZ-domain containing protein, interacting with SAP90/PSD-95-associated protein (SAPAP), the NMDA receptor, and neuronal adhesion molecules. Additionally, interaction of the PH-domain of rat MAGUIN-1 with the kinase domain of Raf could be confirmed in vitro and in vivo, but there is no evidence for the activation of Raf or its recruitment to the plasma membrane by rat MAGUIN-1.

[0011] To date, the precise function of rat MAGUIN-1 and rat MAGUIN-2 is still not clear. Some clues for the role of rat MAGUIN-1 in the cellular context come from particular protein domains and motifs, specific brain expression patterns, and structural homologies to other proteins like CNK (connector enhancer of kinase suppressor of ras (ksr)), as described for the fruit fly. CNK binds kinase suppressor for Ras and Raf kinase, functions in the Ras/MAP kinase pathway, and has been found to play a profound role in the regulation of eye development (Therrien et al., *Cell* 1998, 95: 343-353). On the basis of the similarities between *Drosophila* CNK (contains SAM, PDZ and PH-domains) and rat MAGUIN-1, rat MAGUIN-1 is discussed as a rodent homolog to CNK. Thus, it is likely that rat MAGUIN-1 assembles components of synaptic junctions and regulators of the MAP kinase pathway and links them to NMDA receptors and neuronal adhesion molecules. To date, no experiments have been described that show a relationship between a differential expression of human MAGUIN genes, neither on a transcriptional nor on a translational level, and the pathology of neurodegenerative disorders.

[0012] The disclosure in the present invention of the human MAGUIN-1 gene and the identification of a link of both human MAGUIN-1 and/or human MAGUIN-2 to neurodegenerative diseases, particularly Alzheimer's disease, offers new ways, inter alia, for the diagnosis and treatment of such diseases.

[0013] The singular forms "a", "an", and "the" as used herein and in the claims include plural reference unless the context dictates otherwise. For example "a cell" means as well a plurality of cells, and so forth. The term "and/or" as used in the present specification and in the claims implies that the phrases before and after this term are to be considered either as alternatives or in combination. For instance, the wording "determination of a level and/or an activity" means that either only a level, or only an activity, or both a level and an activity are determined. The term "level" as used herein is meant to comprise a gage of, or a measure of the amount of, or a concentration of a transcription product, for instance an mRNA, or a translation product, for instance a protein or polypeptide. The term "activity" as used herein shall be understood as a measure for the ability of a transcription product or a translation product to produce a biological effect or a measure for a level of biologically active molecules. The term "activity" also refers to enzymatic activity. The terms "level" and/or "activity" further refer to gene expression levels or gene activity. Gene expression can be defined as the utilization of the information contained in a gene by transcription and translation leading to the production of a gene product. "Dysregulation" shall mean an upregulation or downregulation of gene expression. A gene product comprises either RNA or protein and is the result of expression of a gene. The amount of a gene product can be used to measure how active a gene is. The term "gene" as used in the present specification and in the claims comprises both coding regions (exons) as well as non-coding regions (e.g. non-coding regulatory elements such as promoters or enhancers, introns, leader and trailer sequences). The term "ORF" is an acronym for "open reading frame" and refers to a nucleic acid sequence that does not possess a stop codon in at least one reading frame and therefore can potentially be translated into a sequence of amino acids. "Regulatory elements" as used in the present disclosure shall comprise inducible and non-inducible pro-

motors, enhancers, operators and other elements that drive and regulate gene expression. The term "fragment" as used herein is meant to comprise e.g. an alternatively spliced, or truncated, or otherwise cleaved transcription product or translation product. The term "derivative" as used herein refers to a mutant, or an RNA-edited, or a chemically modified, or otherwise altered transcription product, or to a mutant, or chemically modified, or otherwise altered translation product. For instance, a "derivative" may be generated by processes such as altered phosphorylation, or glycosylation, or acetylation, or lipidation, or by altered signal peptide cleavage or other types of maturation cleavage. These processes may occur post-translationally. The term "modulator" as used in the present invention and in the claims refers to a molecule capable of changing or altering the level and/or the activity of a gene, or a transcription product of a gene, or a translation product of a gene. Preferably, a "modulator" is capable of changing or altering the biological activity of a transcription product or a translation product of a gene. Said modulation, for instance, may be an increase or a decrease in enzyme activity, a change in binding characteristics, or any other change or alteration in the biological, functional, or immunological properties of said translation product of a gene.

[0014] The terms "agent", "reagent", or "compound" refer to any substance, chemical, composition or extract that have a positive or negative biological effect on a cell, tissue, body fluid, or within the context of any biological system, or any assay system examined. They can be agonists, antagonists, partial agonists or inverse agonists of a target. Such agents, reagents, or compounds may be nucleic acids, natural or synthetic peptides or protein complexes, or fusion proteins. They may also be antibodies, organic or inorganic molecules or compositions, small molecules, drugs and any combinations of any of said agents above. They may be used for testing, for diagnostic or for therapeutic purposes. The terms "oligonucleotide primer" or "primer" refer to short nucleic acid sequences which can anneal to a given target polynucleotide by hybridization of the complementary base pairs and can be extended by a polymerase. They may be chosen to be specific to a particular sequence or they may be randomly selected, e.g. they will prime all possible sequences in a mix. The length of primers used herein may vary from 10 nucleotides to 80 nucleotides. "Probes" are short nucleic acid sequences of the nucleic acid sequences described and disclosed herein or sequences complementary therewith. They may comprise full length sequences, or fragments, derivatives, isoforms, or variants of a given sequence. The identification of hybridization complexes between a "probe" and an assayed sample allows the detection of the presence of other similar sequences within that sample. As used herein, "homolog or homology" is a term used in the art to describe the relatedness of a nucleotide or peptide sequence to another nucleotide or peptide sequence, which is determined by the degree of identity and/or similarity between said sequences compared.

[0015] The term "variant" as used herein refers to any polypeptide and protein, in reference to polypeptides and proteins disclosed in the present invention, in which one or more amino acids are added and/or substituted and/or deleted and/or inserted at the N-terminus, and/or the C-terminus, and/or within the native amino acid sequences of the native polypeptides or proteins of the present invention. Furthermore, the term "variant" shall include any shorter or

longer version of a polypeptide or protein. "Variants" shall also comprise a sequence that has at least about 80% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% sequence identity with the amino acid sequences of SEQ ID NO. 1 and/or SEQ ID NO. 2, respectively. Derivatives, variants, and fragments may include, but are not limited to, a functional SAM, a functional PDZ and a functional PH domain or other functional modules within the polypeptide sequence of human MAGUIN-1 and/or human Maguin-2 proteins. "Variants" of a protein molecule shown in SEQ ID NO. 1 and/or SEQ ID NO. 2 may include, for example, proteins with conservative amino acid substitutions in highly conservative regions. For example, isoleucine, valine and leucine can each be substituted for one another. Aspartate and glutamate can be substituted for each other. Glutamine and asparagine can be substituted for each other. Serine and threonine can be substituted for each other. Amino acid substitutions in less conservative regions include, for example, isoleucine, valine and leucine, which can each be substituted for one another. Aspartate and glutamate can be substituted for each other. Glutamine and asparagine can be substituted for each other. Serine and threonine can be substituted for each other. Glycine and alanine can be substituted for each other. Alanine and valine can be substituted for each other. Methionine can be substituted for each of leucine, isoleucine or valine, and vice versa. Lysine and arginine can be substituted for each other. One of aspartate and glutamate can be substituted for one of arginine or lysine, and vice versa. Histidine can be substituted for arginine or lysine, and vice versa. Glutamine and glutamate can be substituted for each other. Asparagine and aspartate can be substituted for each other. Other examples of protein modifications include glycosylation and further post-translational modifications. "Proteins and polypeptides" of the present invention include variants, fragments and chemical derivatives of the protein comprising SEQ ID NO. 1 and/or SEQ ID NO. 2. They can include proteins and polypeptides which can be isolated from nature or which can be produced by recombinant and/or synthetic means. Native proteins or polypeptides refer to naturally-occurring truncated or secreted forms, naturally occurring variant forms (e.g. splice variants) and naturally occurring allelic variants. As used herein, protein and polypeptide refers to a linear series of amino acid residues connected to one another by peptide bonds between the alpha-amino group and carboxy groups of adjacent amino acid residues. Other covalent bonds, such as amide and disulfide bonds, may also be present. The term "isolated" as used herein is considered to refer to molecules that are removed from their natural environment, i.e. isolated from a cell or from a living organism in which they normally occur, and that are separated or essentially purified from the coexisting components with which they are found to be associated in nature. This notion further means that the sequences encoding such molecules can be linked by the hand of man to polynucleotides, to which they are not linked in their natural state, and that such molecules can be produced by recombinant and/or synthetic means. Even if for said purposes those sequences may be introduced into living or non-living organisms by methods known to those skilled in the art, and even if those sequences are still present in said organisms, they are still considered to be isolated. In the present invention, the terms "risk", "susceptibility" and "predisposition" are tantamount

and are used with respect to the probability of developing a neurodegenerative disease, preferably Alzheimer's disease.

[0016] The term 'AD' shall mean Alzheimer's disease. "AD-type neuropathology" as used herein refers to neuropathological, neurophysiological, histopathological and clinical hallmarks as described in the instant invention and as commonly known from state-of-the-art literature (see: Iqbal, Swaab, Winblad and Wisniewski, *Alzheimer's Disease and Related Disorders (Etiology, Pathogenesis and Therapeutics)*, Wiley & Sons, New York, Weinheim, Toronto, 1999; Scinto and Daffner, *Early Diagnosis of Alzheimer's Disease*, Humana Press, Totowa, N.J., 2000; Mayeux and Christen, *Epidemiology of Alzheimer's Disease: From Gene to Prevention*, Springer Press, Berlin, Heidelberg, N.Y., 1999; Younkin, Tanzi and Christen, *Presenilins and Alzheimer's Disease*, Springer Press, Berlin, Heidelberg, N.Y., 1998).

[0017] Neurodegenerative diseases or disorders according to the present invention comprise Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Pick's disease, fronto-temporal dementia, progressive nuclear palsy, corticobasal degeneration, cerebro-vascular dementia, multiple system atrophy, argyrophilic grain dementia and other tauopathies, and mild-cognitive impairment. Further conditions involving neurodegenerative processes are, for instance, age-related macular degeneration, narcolepsy, motor neuron diseases, prion diseases, traumatic nerve injury and repair, and multiple sclerosis.

[0018] In one aspect, the invention features a method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease. The method comprises: determining a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject and comparing said level, and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

[0019] The invention also relates to the construction and the use of primers and probes which are unique to the nucleic acid sequences, or fragments, or variants thereof, as disclosed in the present invention. The oligonucleotide primers and/or probes can be labeled specifically with fluorescent, bioluminescent, magnetic, or radioactive substances. The invention further relates to the detection and the production of said nucleic acid sequences, or fragments and variants thereof, using said specific oligonucleotide primers in appropriate combinations. PCR-analysis, a method well known to those skilled in the art, can be performed with said primer combinations to amplify said gene specific nucleic acid sequences from a sample containing nucleic acids. Such sample may be derived either from healthy or diseased subjects. Whether an amplification results in a specific nucleic acid product or not, and whether a fragment of different length can be obtained or not, may be indicative for a neurodegenerative disease, in particular Alzheimer's dis-

ease. Thus, the invention provides nucleic acid sequences, oligonucleotide primers, and probes of at least 10 bases in length up to the entire coding and gene sequences, useful for the detection of gene mutations and single nucleotide polymorphisms in a given sample comprising nucleic acid sequences to be examined, which may be associated with neurodegenerative diseases, in particular Alzheimer's disease. This feature has utility for developing rapid DNA-based diagnostic tests, preferably also in the format of a kit.

[0020] In a further aspect, the invention features a method of monitoring the progression of a neurodegenerative disease in a subject. A level, or an activity, or both said level and said activity, of (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from said subject is determined. Said level and/or said activity is compared to a reference value representing a known disease or health status. Thereby the progression of said neurodegenerative disease in said subject is monitored.

[0021] In still a further aspect, the invention features a method of evaluating a treatment for a neurodegenerative disease, comprising, determining a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment; or derivative, or variant of said transcription or translation product in a sample obtained from a subject being treated for said disease. Said level, or said activity, or both said level and said activity are compared to a reference value representing a known disease or health status, thereby evaluating the treatment for said neurodegenerative disease.

[0022] In a preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said gene coding for the membrane-associated guanylate kinase-interacting proteins is the gene coding for the human neuronal membrane-associated guanylate kinase-interacting protein 1 (SEQ ID NO. 5), also termed (MAGUIN-1), and the human neuronal membrane-associated guanylate kinase-interacting protein 2 (SEQ ID NO. 6).

[0023] In a further preferred embodiment of the herein claimed methods, kits, recombinant animals, molecules, assays, and uses of the instant invention, said neurodegenerative disease or disorder is Alzheimer's disease, and said subjects suffer from Alzheimer's disease.

[0024] The present invention discloses the differential expression and regulation of the human MAGUIN-1 and/or human MAGUIN-2 gene in specific brain regions of Alzheimer's disease patients. Consequently, human MAGUIN-1 and/or human MAGUIN-2 and their corresponding translation products may have a causative role in the regional selective neuronal degeneration typically observed in Alzheimer's disease. Alternatively, human MAGUIN-1 and/or human MAGUIN-2 may confer a neuroprotective function to the remaining surviving nerve cells. Based on these disclosures, the present invention has utility for the diagnostic evaluation and prognosis as well as for the identi-

cation of a predisposition to a neurodegenerative disease, in particular Alzheimer's disease. Furthermore, the present invention provides methods for the diagnostic monitoring of patients undergoing treatment for such a disease.

[0025] It is preferred that the sample to be analyzed and determined is selected from the group comprising brain tissue, or other tissues, or other body cells. The sample can also comprise cerebrospinal fluid or other body fluids including saliva, urine, serum plasma, or mucus. Preferably, the methods of diagnosis, prognosis, monitoring the progression or evaluating a treatment for a neurodegenerative disease, according to the instant invention, can be practiced *ex corpore*, and such methods preferably relate to samples, for instance, body fluids or cells, removed, collected, or isolated from a subject or patient.

[0026] In further preferred embodiments, said reference value is that of a level, or an activity, or both said level and said activity of (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a sample from a subject not suffering from said neurodegenerative disease.

[0027] In preferred embodiments, an alteration in the level and/or activity of a transcription product of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or a translation product of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 protein in a sample cell, or tissue, or body fluid from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of becoming diseased with a neurodegenerative disease, particularly Alzheimer's disease.

[0028] In preferred embodiments, measurement of the level of transcription products of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 is performed in a sample from a subject using a quantitative PCR-analysis with primer combinations to amplify said gene specific sequences from cDNA obtained by reverse transcription of RNA extracted from a sample of a subject. A Northern blot with probes specific for said gene can also be applied. It might also be preferred to measure transcription products by means of chip-based micro-array technologies. These techniques are known to those of ordinary skill in the art (see Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, Mass., 2000). An example of an immunoassay is the detection and measurement of enzyme activity as disclosed and described in the patent application WO 02/14543.

[0029] Furthermore, the level and/or an activity of a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or a fragment, or derivative, or variant of said translation product, and/or the level of activity of said translation product, and/or a fragment, or derivative, or variant thereof, can be detected using an immunoassay, an activity assay, and/or a binding assay. These assays can measure the amount of binding between said protein molecule and an anti-protein antibody by the use of enzymatic, chromodynamic, radioactive, magnetic, or

luminescent labels which are attached to either the anti-protein antibody or a secondary antibody which binds the anti-protein antibody. In addition, other high affinity ligands may be used. Immunoassays which can be used include e.g. ELISAs, Western blots and other techniques known to those of ordinary skill in the art (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1999 and Edwards R, *Immunodiagnosics: A Practical Approach*, Oxford University Press, Oxford; England, 1999). All these detection techniques may also be employed in the format of microarrays, protein-arrays, antibody microarrays, tissue microarrays, electronic biochip or protein-chip based technologies (see Schena M., *Microarray Biochip Technology*, Eaton Publishing, Natick, Mass., 2000).

[0030] In a preferred embodiment, the level, or the activity, or both said level and said activity of (i) a transcription product of human MAGUIN-1 and/or human MAGUIN-2, and/or of (ii) a translation product of human MAGUIN-1 and/or human MAGUIN-2, and/or of (iii) a fragment, or derivative, or variant of said transcription or translation product in a series of samples taken from said subject over a period of time is compared, in order to monitor the progression of said disease. In further preferred embodiments, said subject receives a treatment prior to one or more of said sample gatherings. In yet another preferred embodiment, said level and/or activity is determined before and after said treatment of said subject.

[0031] In another aspect, the invention features a kit for diagnosing or prognosticating neurodegenerative diseases, in particular Alzheimer's disease, in a subject, or determining the propensity or predisposition of a subject to develop a neurodegenerative disease, in particular Alzheimer's disease, said kit comprising:

[0032] (a) at least one reagent which is selected from the group consisting of (i) reagents that selectively detect a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 (ii) reagents that selectively detect a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2; and

[0033] (b) instruction for diagnosing, or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of a subject to develop such a disease by

[0034] detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, in a sample from said subject; and

[0035] diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of said subject to develop such a disease,

[0036] wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value

representing a known disease status, indicates a diagnosis or prognosis of a neurodegenerative disease, in particular Alzheimer's disease, or an increased propensity or predisposition of developing such a disease. The kit, according to the present invention, may be particularly useful for the identification of individuals that are at risk of developing a neurodegenerative disease, in particular Alzheimer's disease. Consequently, the kit, according to the invention, may serve as a means for targeting identified individuals for early preventive measures or therapeutic intervention prior to disease onset, before irreversible damage in the course of the disease has been inflicted. Furthermore, in preferred embodiments, the kit featured in the invention is useful for monitoring a progression of a neurodegenerative disease, in particular Alzheimer's disease, in a subject, as well as monitoring success or failure of therapeutic treatment for such a disease of said subject.

[0037] In another aspect, the invention features a method of treating or preventing a neurodegenerative disease, in particular Alzheimer's disease, in a subject comprising the administration to said subject in a therapeutically or prophylactically effective amount of an agent or agents which directly or indirectly affect a level, or an activity, or both said level and said activity, of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of said gene, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). Said agent may comprise a small molecule, or it may also comprise a peptide, an oligopeptide, or a polypeptide. Said peptide, oligopeptide, or polypeptide may comprise an amino acid sequence shown in SEQ ID NO.1 and/or SEQ ID NO.2, or a fragment, or derivative, or variant thereof. An agent for treating or preventing a neurodegenerative disease, in particular AD, according to the instant invention, may also consist of a nucleotide, an oligonucleotide, or a polynucleotide. Said oligonucleotide or polynucleotide may comprise a nucleotide sequence of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 protein, either in sense orientation or in antisense orientation.

[0038] In preferred embodiments, the method comprises the application of per se known methods of gene therapy and/or antisense nucleic acid technology to administer said agent or agents. In general, gene therapy includes several approaches: molecular replacement of a mutated gene, addition of a new gene resulting in the synthesis of a therapeutic protein, and modulation of endogenous cellular gene expression by recombinant expression methods or by drugs. Gene-transfer techniques are described in detail (see e.g. Behr, *Acc Chem Res* 1993, 26: 274-278 and Mulligan, *Science* 1993, 260: 926-931; the contents of which are incorporated herein by reference) and include direct gene-transfer techniques such as mechanical microinjection of DNA into a cell as well as indirect techniques employing biological vectors (like recombinant viruses, especially retroviruses) or model liposomes, or techniques based on transfection with DNA coprecipitation with polycations, cell membrane perturbation by chemical (solvents, detergents, polymers, enzymes) or physical means (mechanic, osmotic, thermic, electric shocks). The postnatal gene transfer into the central nervous system has been described in detail (see e.g. Wolff, *Curr Opin Neurobiol* 1993, 3: 743-748).

[0039] In particular, the invention features a method of treating or preventing a neurodegenerative disease by means of antisense nucleic acid therapy, i.e. the down-regulation of an inappropriately expressed or defective gene by the introduction of antisense nucleic acids or derivatives thereof into certain critical cells (see e.g. Gillespie, *DN&P* 1992, 5: 389-395; Agrawal and Akhtar, *Trends Biotechnol* 1995, 13: 197-199; Crooke, *Biotechnology* 1992, 10: 882-6). Apart from hybridization strategies, the application of ribozymes, i.e. RNA molecules that act as enzymes, destroying RNA that carries the message of disease has also been described (see e.g. Barinaga, *Science* 1993, 262: 1512-1514). In preferred embodiments, the subject to be treated is a human, and therapeutic antisense nucleic acids or derivatives thereof are directed against human MAGUIN-1 and/or human MAGUIN-2. It is preferred that cells of the central nervous system, preferably the brain, of a subject are treated in such a way. Cell penetration can be performed by known strategies such as coupling of antisense nucleic acids and derivatives thereof to carrier particles, or the above described techniques. Strategies for administering targeted therapeutic oligodeoxynucleotides are known to those of skill in the art (see e.g. Wickstrom, *Trends Biotechnol* 1992, 10: 281-287). In some cases, delivery can be performed by mere topical application. Further approaches are directed to intracellular expression of antisense RNA. In this strategy, cells are transformed ex vivo with a recombinant gene that directs the synthesis of an RNA that is complementary to a region of target nucleic acid. Therapeutical use of intracellularly expressed antisense RNA is procedurally similar to gene therapy. A recently developed method of regulating the intracellular expression of genes by the use of double-stranded RNA, known variously as RNA interference (RNAi), can be another effective approach for nucleic acid therapy (Hannon, *Nature* 2002, 418: 244-251).

[0040] In further preferred embodiments, the method comprises grafting donor cells into the central nervous system, preferably the brain, of said subject, or donor cells preferably treated so as to minimize or reduce graft rejection, wherein said donor cells are genetically modified by insertion of at least one transgene encoding said agent or agents. Said transgene might be carried by a viral vector, in particular a retroviral vector. The transgene can be inserted into the donor cells by a nonviral physical transfection of DNA encoding a transgene, in particular by microinjection. Insertion of the transgene can also be performed by electroporation, chemically mediated transfection, in particular calcium phosphate transfection, or liposomal mediated transfection (see Mc Celland and Pardee, *Expression Genetics: Accelerated and High-Throughput Methods*, Eaton Publishing, Natick, Mass., 1999).

[0041] In preferred embodiments, said agent for treating and preventing a neurodegenerative disease, in particular AD, is a therapeutic protein which can be administered to said subject, preferably a human, by a process comprising introducing subject cells into said subject, said subject cells having been treated in vitro to insert a DNA segment encoding said therapeutic protein, said subject cells expressing in vivo in said subject a therapeutically effective amount of said therapeutic protein. Said DNA segment can be inserted into said cells in vitro by a viral vector, in particular a retroviral vector.

[0042] Methods of treatment, according to the present invention, comprise the application of therapeutic cloning, transplantation, and stem cell therapy using embryonic stem cells or embryonic germ cells and neuronal adult stem cells, combined with any of the previously described cell- and gene therapeutic methods. Stem cells may be totipotent or pluripotent. They may also be organ-specific. Strategies for repairing diseased and/or damaged brain cells or tissue comprise (i) taking donor cells from an adult tissue. Nuclei of those cells are transplanted into unfertilized egg cells from which the genetic material has been removed. Embryonic stem cells are isolated from the blastocyst stage of the cells which underwent somatic cell nuclear transfer. Use of differentiation factors then leads to a directed development of the stem cells to specialized cell types, preferably neuronal cells (Lanza et al., *Nature Medicine* 1999, 9: 975-977), or (ii) purifying adult stem cells, isolated from the central nervous system, or from bone marrow (mesenchymal stem cells), for in vitro expansion and subsequent grafting and transplantation, or (iii) directly inducing endogenous neural stem cells to proliferate, migrate, and differentiate into functional neurons (Peterson D A, *Curr. Opin. Pharmacol.* 2002, 2: 34-42). Adult neural stem cells are of great potential for repairing damaged or diseased brain tissues, as the germinal centers of the adult brain are free of neuronal damage or dysfunction (Colman A, *Drug Discovery World* 2001, 7: 66-71).

[0043] In preferred embodiments, the subject for treatment or prevention, according to the present invention, can be a human, an experimental animal, e.g. a mouse or a rat, a domestic animal, or a non-human primate. The experimental animal can be an animal model for a neurodegenerative disorder, e.g. a transgenic mouse and/or a knock-out mouse with a neurodegenerative phenotype, in particular with an Alzheimer's-type neuropathology.

[0044] In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

[0045] In an additional aspect, the invention features a pharmaceutical composition comprising said modulator and preferably a pharmaceutical carrier. Said carrier refers to a diluent, adjuvant, excipient, or vehicle with which the modulator is administered.

[0046] In a further aspect, the invention features a modulator of an activity, or a level, or both said activity and said level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for use in a pharmaceutical composition.

[0047] In another aspect, the invention provides for the use of a modulator of an activity, or a level, or both said activity and said level of at least one substance which is

selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for a preparation of a medicament for treating or preventing a neurodegenerative disease, in particular Alzheimer's disease.

[0048] In one aspect, the present invention also provides a kit comprising one or more containers filled with a therapeutically or prophylactically effective amount of said pharmaceutical composition.

[0049] In a further aspect, the invention features a recombinant, non-human animal comprising a non-native gene sequence coding for human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or a variant, or a derivative thereof. The generation of said recombinant, non-human animal comprises (i) providing a gene targeting construct containing said gene sequence and a selectable marker sequence, and (ii) introducing said targeting construct into a stem cell of a non-human animal, and (iii) introducing said non-human animal stem cell into a non-human embryo, and (iv) transplanting said embryo into a pseudopregnant non-human animal, and (v) allowing said embryo to develop to term, and (vi) identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and (vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said gene is mis-expressed, or under-expressed, or over-expressed, and wherein said disruption or alteration results in said non-human animal exhibiting a predisposition to developing symptoms of neuropathology similar to a neurodegenerative disease, in particular Alzheimer's disease. Strategies and techniques for the generation and construction of such an animal are known to those of ordinary skill in the art (see e.g. Capecchi, *Science* 1989, 244: 1288-1292 and Hogan et al., 1994, *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Jackson and Abbott, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press, Oxford, England, 1999). It is preferred to make use of such a recombinant non-human animal as an animal model for investigating neurodegenerative diseases, in particular Alzheimer's disease. Such an animal may be useful for screening, testing and validating compounds, agents and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.

[0050] In another aspect, the invention features an assay for screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases and disorders of one or more substances selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii). This screening method comprises (a) contacting a cell with a test compound, and (b) measuring the activity, or the level,

or both the activity and the level of one or more substances recited in (i) to (iv), and (c) measuring the activity, or the level, or both the activity and the level of said substances in a control cell not contacted with said test compound, and (d) comparing the levels of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of said substances in the contacted cells indicates that the test compound is a modulator of said diseases and disorders.

[0051] In one further aspect, the invention features a screening assay for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases and disorders of one or more substances selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii), comprising (a) administering a test compound to a test animal which is predisposed to developing or has already developed symptoms of a neurodegenerative disease or related diseases or disorders, and (b) measuring the activity and/or level of one or more substances recited in (i) to (iv), and (c) measuring the activity and/or level of said substances in a matched control animal which is equally predisposed to developing or has already developed said symptoms and to which animal no such test compound has been administered, and (d) comparing the activity and/or level of the substance in the animals of step (b) and (c), wherein an alteration in the activity and/or level of substances in the test animal indicates that the test compound is a modulator of said diseases and disorders.

[0052] In a preferred embodiment, said test animal and/or said control animal is a recombinant, non-human animal which expresses the gene coding for human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or derivative, or a variant thereof, under the control of a transcriptional regulatory element which is not the native human MAGUIN-1 and/or human MAGUIN-2 gene transcriptional control regulatory element.

[0053] In another embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a modulator of neurodegenerative diseases by a method of the aforementioned screening assays and (ii) admixing the modulator with a pharmaceutical carrier. However, said modulator may also be identifiable by other types of screening assays.

[0054] In another aspect, the present invention provides for an assay for testing a compound, preferably for screening a plurality of compounds, for inhibition of binding between a ligand and human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or derivative, or variant thereof. Said screening assay comprises the steps of (i) adding a liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or derivative, or variant thereof, to a plurality of containers, and (ii) adding a compound or a plurality of compounds to be screened for said inhibition to said plurality of containers, and (iii) adding fluorescently labelled ligand to said containers, and (iv) incubating said human MAGUIN-1 and/or human MAGUIN-2, or said fragment, or derivative, or variant thereof, and said compound or plurality of compounds, and said fluorescently labelled ligand, and

(v) measuring the amounts of fluorescence associated with said human MAGUIN-1 and/or human MAGUIN-2, or with said fragment, or derivative, or variant thereof, and (vi) determining the degree of inhibition by one or more of said compounds of binding of said ligand to said human MAGUIN-1 and/or human MAGUIN-2, or said fragment, or derivative, or variant thereof. Instead of utilizing a fluorescently labelled ligand, it might in some aspects be preferred to use any other detectable label known to the person skilled in the art, e.g. radioactive labels, and detect it accordingly. Said method may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to inhibit the binding of a ligand to a gene product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or derivative, or variant thereof. One example of a fluorescent binding assay, in this case based on the use of carrier particles, is disclosed and described in patent application WO 00/52451. A further example is the competitive assay method as described in patent WO 02/01226. Preferred signal detection methods for screening assays of the instant invention are described in the following patent applications: WO 96/13744, WO 98/16814, WO 98/23942, WO 99/17086, WO 99/34195, WO 00/66985, WO 01/59436, WO 01/59416.

[0055] In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as an inhibitor of binding between a ligand and a gene product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 by the aforementioned inhibitory binding assay and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

[0056] In another aspect, the invention features an assay for testing a compound, preferably for screening a plurality of compounds to determine the degree of binding of said compounds to human MAGUIN-1 and/or human MAGUIN-2, or to a fragment, a variant, or derivative thereof. Said screening assay comprises (i) adding a liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or a fragment, or a variant, or derivative thereof, to a plurality of containers, and (ii) adding a fluorescently labelled compound or a plurality of fluorescently labelled compounds to be screened for said binding to said plurality of containers, and (iii) incubating said human MAGUIN-1 and/or human MAGUIN-2, or said fragment, or variant, or derivative thereof, and said fluorescently labelled compound or fluorescently labelled compounds, and (iv) measuring the amounts of fluorescence associated with said human MAGUIN-1 and/or human MAGUIN-2, or with said fragment, or variant, or derivative thereof, and (v) determining the degree of binding by one or more of said compounds to said human MAGUIN-1 and/or human MAGUIN-2, or said fragment, or variant, or derivative thereof. In this type of assay it might be preferred to use a fluorescent label. However, any other type of detectable label might also be employed. Said method may be useful for the identification of novel compounds as well as for evaluating compounds which have been improved or otherwise optimized in their ability to bind to a human MAGUIN-1 and/or human MAGUIN-2 gene product, or fragment, or variant, or derivative thereof.

[0057] In one further embodiment, the present invention provides a method for producing a medicament comprising the steps of (i) identifying a compound as a binder to a gene product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 by the aforementioned binding assays and (ii) admixing the compound with a pharmaceutical carrier. However, said compound may also be identifiable by other types of screening assays.

[0058] In another embodiment, the present invention provides for a medicament obtainable by any of the methods according to the herein claimed screening assays. In one further embodiment, the instant invention provides for a medicament obtained by any of the methods according to the herein claimed screening assays.

[0059] The present invention features protein molecules shown in SEQ ID NO. 1, and SEQ ID NO. 2, or fragments, or derivatives, or variants thereof, for use as diagnostic targets for detecting a neurodegenerative disease, preferably Alzheimer's disease.

[0060] The present invention further features protein molecules shown in SEQ ID NO. 1 and SEQ ID NO. 2, or fragments, or derivatives, or variants thereof, for use as screening targets for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

[0061] The invention further features an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of the human MAGUIN-1 gene shown in SEQ ID NO. 1, or a fragment, or a variant, or a derivative thereof. The immunogen may comprise immunogenic or antigenic epitopes or portions of a translation product of said gene, wherein said immunogenic or antigenic portion of a translation product is a polypeptide, and wherein said polypeptide elicits an antibody response in an animal, and wherein said polypeptide is immunospecifically bound by said antibody. Methods for generating antibodies are well known in the art (see Harlow et al., *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988). The term "antibody", as employed in the present invention, encompasses all forms of antibodies known in the art, such as polyclonal, monoclonal, chimeric, recombinatorial, anti-idiotypic, humanized, or single chain antibodies, as well as fragments thereof (see Dubel and Breitling, *Recombinant Antibodies*, Wiley-Liss, New York, N.Y., 1999). Antibodies of the present invention are useful, for instance, in a variety of diagnostic and therapeutic methods, based on state-in-the-art techniques (see Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1999 and Edwards R., *Immunodiagnosics: A Practical Approach*, Oxford University Press, Oxford, England, 1999) such as enzyme-immuno assays (e.g. enzyme-linked immunosorbent assay, ELISA), radioimmuno assays, chemoluminescence-immuno assays, Western-blot, immunoprecipitation and antibody microarrays. These methods involve the detection of translation products of the human MAGUIN-1 gene.

[0062] The invention also features an antibody specifically immunoreactive with an immunogen, wherein said immunogen is a translation product of the human MAGUIN-2 gene shown in SEQ ID NO. 2, or a fragment, a variant, or a derivative thereof.

[0063] In a preferred embodiment of the present invention, said antibodies can be used for detecting the pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell. The invention is particularly suited to detect pathological structures in the brain of a subject. It is also especially suited to detect pathological cells of the muscular system, prostate, stomach, testis, ovary, adrenal glands, mammary glands, liver, spleen, lung, trachea or placenta.

[0064] Preferably, the pathological state relates to a neurodegenerative disease, in particular to Alzheimer's disease. Immunocytochemical staining of a cell can be carried out by a number of different experimental methods well known in the art. It might be preferred, however, to apply an automated method for the detection of antibody binding, wherein the determination of the degree of staining of a cell, or the determination of the cellular or subcellular staining pattern of a cell, or the topological distribution of an antigen on the cell surface or among organelles and other subcellular structures within the cell, are carried out according to the method described in U.S. Pat. No. 6,150,173.

[0065] Other features and advantages of the invention will be apparent from the following description of figures and examples which are illustrative only and not intended to limit the remainder of the disclosure in any way.

[0066] **FIG. 1** depicts the brain regions with selective vulnerability to neuronal loss and degeneration in Alzheimer's disease. Primarily, neurons within the inferior temporal lobe, the entorhinal cortex, the hippocampus, and the amygdala are subject to degenerative processes in Alzheimer's disease (Terry et al., *Annals of Neurology* 1981, 10:184-192). These brain regions are mostly involved in the processing of learning and memory functions. In contrast, neurons within the frontal cortex, the occipital cortex, and the cerebellum remain largely intact and preserved from neurodegenerative processes in Alzheimer's disease. Brain tissues from the frontal cortex (F), the temporal cortex (T), and the hippocampus (H) of Alzheimer's disease patients and healthy, age-matched control individuals were used for the herein disclosed examples. For illustrative purposes, the image of a normal healthy brain was taken from a publication by Strange (*Brain Biochemistry and Brain Disorders*, Oxford University Press, Oxford, 1992, p.4).

[0067] **FIG. 2** discloses the initial identification of the differential expression of the human MAGUIN-1 gene in a fluorescence differential display screen. The figure shows a clipping of a large preparative fluorescent differential display gel. PCR products from the frontal cortex (F) and the temporal cortex (T) of two healthy control subjects and six Alzheimer's diseased patients were loaded in duplicate onto a denaturing polyacrylamide gel (from left to right). PCR products were obtained by amplification of the individual cDNAs with the corresponding one-base-anchor oligonucleotide and the specific Cy3 labelled random primers. The arrow indicates the lane where significant differences in intensity of the signals for human MAGUIN-1 transcript derived from frontal cortex, compared to the signals for human MAGUIN-1 transcript derived from the temporal cortex of Alzheimer's patients exist. The differential expres-

sion reflects a down-regulation of human MAGUIN RNA expression in the temporal cortex in comparison to the frontal cortex of AD patients. Comparing the signals derived from frontal cortex and temporal cortex of healthy non-AD control subjects with each other, no distinction in signal intensity, i.e. no altered expression level can be detected.

[0068] **FIG. 3** and **FIG. 4** illustrate the verification of the differential expression of human MAGUIN-1 in AD brain tissues by quantitative RT-PCR analysis. Quantification of RT-PCR products from RNA samples collected from the frontal cortex (F) and the temporal cortex (T) of AD patients (**FIG. 3a**) and samples from the frontal cortex (F) and the hippocampus (H) of AD patients (**FIG. 4a**) was performed by the LightCycler rapid thermal cycling technique. Likewise, samples of healthy, age-matched control individuals were compared (**FIG. 3b** for frontal cortex and temporal cortex, **FIG. 4b** for frontal cortex and hippocampus). The data were normalized to the combined average values of a set of standard genes which showed no significant differences in their gene expression levels. Said set of standard genes consisted of genes for cyclophilin B, the ribosomal protein S9, the transferrin receptor, GAPDH, and beta-actin. The figure depicts the kinetics of amplification by plotting the cycle number against the amount of amplified material as measured by its fluorescence. Note that the amplification kinetics of Maguin-1 cDNA from both, the frontal and temporal cortices of a normal control individual, and from the frontal cortex and hippocampus of a normal control individual, respectively, during the exponential phase of the reaction are juxtaposed (**FIGS. 3b** and **4b**, arrowheads), whereas in Alzheimer's disease (**FIGS. 3a** and **4a**, arrowheads) there is a significant separation of the corresponding curves, indicating a differential expression of Maguin-1 in the respective analyzed brain regions.

[0069] **FIG. 5** and **FIG. 6** illustrate the verification of the differential expression of human MAGUIN-2 in AD brain tissues by quantitative RT-PCR analysis. Quantification of RT-PCR products from RNA samples collected from the frontal cortex (F) and the temporal cortex (T) of AD patients (**FIG. 5a**) and samples from the frontal cortex (F) and the hippocampus (H) of AD patients (**FIG. 6a**) was performed by the LightCycler rapid thermal cycling technique. Likewise, samples of healthy, age-matched control individuals were compared (**FIG. 5b** for frontal cortex and temporal cortex, **FIG. 6b** for frontal cortex and hippocampus). The data were normalized to the combined average values of a set of standard genes which showed no significant differences in their gene expression levels. Said set of standard genes consisted of genes for cyclophilin B, the ribosomal protein S9, the transferrin receptor, GAPDH, and beta-actin. The figure depicts the kinetics of amplification by plotting the cycle number against the amount of amplified material as measured by its fluorescence. Note that the amplification kinetics of Maguin-2 cDNA from both, the frontal and temporal cortices of a normal control individual, and from the frontal cortex and hippocampus of a normal control individual, respectively, during the exponential phase of the reaction are juxtaposed (**FIGS. 5b** and **6b**, arrowheads), whereas in Alzheimer's disease (**FIGS. 5a** and **6a**, arrowheads) there is a significant separation of the corresponding curves, indicating a differential expression of Maguin-2 in the respective analyzed brain regions.

[0070] FIG. 7 discloses the amino acid sequence of the human MAGUIN-1 protein comprising 1034 amino acids; SEQ ID NO. 1. The protein harbors several distinct functional domains which are located as follows: amino acid residues 8 to 75 form the 'Sterile Alpha Motif' (SAM), amino acid residues 156 to 296 constitute the PDZ domain, and the Pleckstrin-homology (PH) domain consists of amino acid residues 572 to 667.

[0071] FIG. 8 shows an alignment of the amino acid sequence of SEQ ID NO.1, human MAGUIN-1, with the rat MAGUIN-1 amino acid sequence (GenBank accession number aad04568). The full length human MAGUIN-1 protein consists of 1034 amino acids (residues given in the single-letter amino acid code).

[0072] FIG. 9 discloses the amino acid sequence of the human MAGUIN-2 protein comprising 898 amino acids; SEQ ID NO. 2. The protein harbors several distinct functional domains which are located as follows: amino acid residues 8 to 75 form the 'Sterile Alpha Motif' (SAM), amino acid residues 156 to 296 constitute the PDZ domain, and the Pleckstrin-homology (PH) domain consists of amino acid residues 572 to 667.

[0073] FIG. 10 shows an alignment of the amino acid sequence of SEQ ID NO. 2, human MAGUIN-2, with rat MAGUIN-2 amino acid sequence (GenBank accession number aad04567). The full length human MAGUIN-2 protein consists of 898 amino acids (residues given in the single-letter amino acid code).

[0074] FIG. 11 represents the nucleotide sequence of SEQ ID NO. 3, the coding sequence of the human MAGUIN-1 gene, comprising 3105 nucleotides.

[0075] FIG. 12 represents the nucleotide sequence of SEQ ID NO. 4, the coding sequence of the human MAGUIN-2 gene, comprising 2697 nucleotides.

[0076] FIG. 13 shows SEQ ID NO. 5, the nucleotide sequence of the human, MAGUIN-1 cDNA, comprising 5749 nucleotides.

[0077] FIG. 14 shows SEQ ID NO. 6, the nucleotide sequence of the human MAGUIN-2 cDNA; comprising 4350 nucleotides.

[0078] FIG. 15 depicts SEQ ID NO. 7, the nucleotide sequence of the 50 bp MAGUIN-1 cDNA fragment, identified and obtained by fluorescence differential display and subsequent cloning.

[0079] FIG. 16 outlines the sequence alignment of SEQ ID NO. 7, the 50 bp human MAGUIN-1 cDNA fragment, with the 3'UTR nucleotide sequence of SEQ ID NO. 5 (nucleotide 5693 to 5742), the nucleotide sequence of human MAGUIN-1 cDNA.

[0080] FIG. 17 charts the schematic alignment of SEQ ID NO. 7, the human MAGUIN-1 cDNA fragment, SEQ ID NO. 6, the human MAGUIN-2 cDNA sequence and the nucleotide sequence of SEQ ID NO. 5, the nucleotide sequence of human MAGUIN-1 cDNA, derived from the alignment of EST nucleotide sequences as found in the GenBank genetic sequence database. EST numbers are written on the left side, all sequences are 5' to 3' directed.

[0081] FIG. 18 depicts human cerebral cortex labeled with an affinity-purified rabbit anti-Maguin-1 antiserum

raised against a peptide corresponding to amino acids 914-928 (green signals). Strong immunoreactivity of human Maguin-1 was detected in neuronal cell bodies (indicated by arrowheads) and in neurites, whereas glial cells were immuno-negative (see arrows). The same immunostaining pattern was observed by using another antiserum raised against a peptide mapping to amino acids 973-987 of Maguin-

[0082] 1. Blue signals indicate nuclei stained with DAPI.

[0083] Table 1 lists the gene expression levels in the frontal cortex relative to the temporal cortex for the human MAGUIN-1 gene in seven Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P017, P019 (1.42 to 4.14 fold) and five healthy, age-matched control individuals, herein identified by internal reference numbers C005, C008, C011, C012, C014 (0.30 to 1.36 fold). The values shown are reciprocal values according to the formula described herein.

[0084] Table 2 lists the gene expression levels in the frontal cortex relative to the hippocampus for the human MAGUIN-1 gene in six Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P019 (1.21 to 3.07 fold) and three healthy, age-matched control individuals, herein identified by internal reference numbers C004, C005, C008 (0.39 to 1.74 fold). The values shown are reciprocal values according to the formula described herein.

[0085] Table 3 lists the gene expression levels in the frontal cortex relative to the temporal cortex for the human MAGUIN-2 gene in seven Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P017, P019 (1.77 to 11.73 fold) and five healthy, age-matched control individuals, herein identified by internal reference numbers C005, C008, C011, C012, C014 (0.30 to 1.42 fold). The values shown are reciprocal values according to the formula described herein.

[0086] Table 4 lists the gene expression levels in the frontal cortex relative to the hippocampus for the human MAGUIN-2 gene in six Alzheimer's disease patients, herein identified by internal reference numbers P010, P011, P012, P014, P016, P019 (0.72 to 9.08 fold) and three healthy, age-matched control individuals, herein identified by internal reference numbers C004, C005, C008 (0.46 to 1.69 fold). The values shown are reciprocal values according to the formula described herein.

EXAMPLE I

[0087] (i) Brain Tissue Dissection from Patients with Alzheimer's Disease:

[0088] Brain tissues from Alzheimer's disease patients and age-matched control subjects were collected within 6 hours post-mortem and immediately frozen on dry ice. Sample sections from each tissue were fixed in paraformaldehyde for histopathological confirmation of the diagnosis. Brain areas for differential expression analysis were identified (see FIG. 1) and stored at -80° C. until RNA extractions were performed.

[0089] (ii) Isolation of Total RNA:

[0090] Total RNA was extracted from post-mortem brain tissue by using the RNeasy kit (Qiagen) according to the

manufacturer's protocol. The accurate RNA concentration and the RNA quality were determined with the DNA LabChip system using the Agilent 2100 Bioanalyzer (Agilent Technologies). For additional quality testing of the prepared RNA, i.e. exclusion of partial degradation and testing for DNA contamination, specifically designed intronic GAPDH oligonucleotides and genomic DNA as reference control were utilised to generate a melting curve with the LightCycler technology as described in the manufacturer's protocol (Roche).

[0091] (iii) cDNA Synthesis and Identification of Differentially Expressed Genes by Fluorescence Differential Display (FDD):

[0092] In order to identify changes in gene expression in different tissues we employed a modified and improved differential display (DD) screening method. The original DD screening method is known to those skilled in the art (Liang and Pardee, *Science* 1995, 267:1186-7). This technique compares two populations of RNA and provides clones of genes that are expressed in one population but not in the other. Several samples can be analyzed simultaneously and both up- and down-regulated genes can be identified in the same experiment. By adjusting and refining several steps in the DD method as well as modifying technical parameters, e.g. increasing redundancy, evaluating optimized reagents and conditions for reverse transcription of total RNA, optimizing polymerase chain reactions (PCR) and separation of the products thereof, a technique was developed which allows for highly reproducible and sensitive results. The applied and improved DD technique was described in detail by von der Kammer et al. (*Nucleic Acids Research* 1999, 27: 2211-2218). A set of 64 specifically designed random primers were developed (standard set) to achieve a statistically comprehensive analysis of all possible RNA species. Further, the method was modified to generate a preparative DD slab-gel technique, based on the use of fluorescently labelled primers. In the present invention, RNA populations from carefully selected post-mortem brain tissues (frontal and temporal cortex) of Alzheimer's disease patients and age-matched control subjects were compared.

[0093] As starting material for the DD analysis we used total RNA, extracted as described above (ii). Equal amounts of 0.05 μ g RNA each were transcribed into cDNA in 20 μ l reactions containing 0.5 mM each dNTP, 1 μ l Sensiscript™ Reverse Transcriptase and 1 \times RT buffer (Qiagen), 10 U RNase inhibitor (Qiagen) and 1 μ M of either one-base-anchor oligonucleotides HT₁₁A, HT₁₁G or HT₁₁C (Liang et al., *Nucleic Acids Research* 1994, 22: 5763-5764; Zhao et al., *Biotechniques* 1995, 18: 842-850). Reverse transcription was performed for 60 min at 37° C. with a final denaturation step at 93° C. for 5 min. 2 μ l of the obtained cDNA each was subjected to a polymerase chain reaction (PCR) employing the corresponding one-base-anchor oligonucleotide (1 μ M) along with either one of the Cy3 labelled random DD primers (1 μ M), 1 \times GeneAmp PCR buffer (Applied Biosystems), 1.5 mM MgCl₂ (Applied Biosystems), 2 μ M dNTP-Mix (dATP, dGTP, dCTP, dTTP Amersham Pharmacia Biotech), 5% DMSO (Sigma), 1 U AmpliTaq DNA Polymerase (Applied Biosystems) in a 20 μ l final volume. PCR conditions were set as follows: one round at 94° C. for 30 sec for denaturing, cooling 1° C./sec down to 40° C., 40° C. for 4 min for low-stringency annealing of primer, heating 1° C./sec up to 72° C., 72° C. for 1 min for extension. This

round was followed by 39 high-stringency cycles: 94° C. for 30 sec, cooling 1° C./sec down to 60° C., 60° C. for 2 min, heating 1° C./sec up to 72° C., 72° C. for 1 min. One final step at 72° C. for 5 min was added to the last cycle (PCR cyclor: Multi Cyclor PTC 200, MJ Research). 8 μ l DNA loading buffer were added to the 20 μ l PCR product preparation, denatured for 5 min and kept on ice until loading onto a gel. 3.5 μ l each were separated on 0.4 mm thick, 6%-polyacrylamide (Long Ranger)/7 M urea sequencing gels in a slab-gel system (Hitachi Genetic Systems) at 2000 V, 60W, 30 mA, for 1 h 40 min. Following completion of the electrophoresis, gels were scanned with a FMBIO II fluorescence-scanner (Hitachi Genetic Systems), using the appropriate FMBIO II Analysis 8.0 software. A full-scale picture was printed, differentially expressed bands marked, excised from the gel, transferred into 1.5 ml containers, overlaid with 200 μ l sterile water and kept at -20° C. until extraction.

[0094] Elution and reamplification of differential display products: The differential bands were extracted from the gel by boiling in 200 μ l H₂O for 10 min, cooling down on ice and precipitation from the supernatant fluids by using ethanol (Merck) and glycogen/sodium acetate (Merck) at -20° C. over night, and subsequent centrifugation at 13.000 rpm for 25 min at 4° C. Pellets were washed twice in ice-cold ethanol (80%), resuspended in 10 mM Tris pH 8.3 (Merck) and dialysed against 10% glycerol (Merck) for 1 h at room temperature on a 0.025 μ m VSWP membrane (Millipore). The obtained preparations were used as templates for reamplification by 15 high-stringency cycles in 25- μ l PCR mixtures containing the corresponding primer pairs as used for the differential display PCR (see above) under identical conditions, with the exception of the initial round at 94° C. for 5 min, followed by 15 cycles of: 94° C. for 45 sec, 60° C. for 45 sec, ramp 1° C./sec to 70° C. for 45 sec, and one final step at 72° C. for 5 min.

[0095] Cloning and sequencing of differential display products: Re-amplified cDNAs were analyzed with the DNA LabChip system (Agilent 2100 Bioanalyzer, Agilent Technologies) and were ligated into the pCR-Blunt II-TOPO vector and transformed into *E. coli* Top10F' cells (Zero Blunt TOPO PCR Cloning Kit, Invitrogen) according to the manufacturer's instructions. Cloned cDNA fragments were sequenced by commercially available sequencing facilities. The results of one such fluorescence differential display experiment for the human MAGUIN-1 gene are shown in FIG. 2.

[0096] (iv) Confirmation of Differential Expression by Quantitative RT-PCR:

[0097] Positive corroboration of differential expression of the human MAGUIN-1 gene and human MAGUIN-2 gene was performed using the LightCycler technology (Roche). This technique features rapid thermal cycling for the polymerase chain reaction as well as real-time measurement of fluorescent signals during amplification and therefore allows for highly accurate quantification of RT-PCR products by using a kinetic, rather than an endpoint approach. The ratios of human MAGUIN-1 and human MAGUIN-2 cDNA each from the temporal cortex and frontal cortex, and from the hippocampus and frontal cortex, respectively, were determined (relative quantification).

[0098] First, a standard curve was generated to determine the efficiency of the PCR with specific primers for human MAGUIN-1:

5'-CAGCAAGCAGTTGACGGGA-3'
and
5'-GCCACGAGTCTTGTCAAATCA-3'

[0099] and human MAGUIN-2:

5'-GGGCTCCCAAAGGATAT-3'
and
5'-CCCAATGTAGAAAGCTCGCATT-3'.

[0100] PCR amplification (95° C. and 1 sec, 56° C. and 5 sec, and 72° C. and 5 sec) was performed in a volume of 20 μ l containing Lightcycler-FastStart DNA Master SYBR Green I mix (contains FastStart Taq DNA polymerase, reaction buffer, dNTP mix with dUTP instead of dTTP, SYBR Green I dye, and 1 mM MgCl₂; Roche), 0.5 μ M primers, 2 μ l of a cDNA dilution series (final concentration of 40, 20, 10, 5, 1 and 0.5 ng human total brain cDNA; Clontech) and depending on the primers used, additional 3 mM MgCl₂. Melting curve analysis revealed a single peak at approximately 80° C. and 80.6° C. with no visible primer dimers. Quality and size of the PCR product were determined with the DNA LabChip system (Agilent 2100 Bio-analyzer, Agilent Technologies). A single peak at the expected size of 121 bp for human MAGUIN-1 and 67 bp for human MAGUIN-2 was observed in the electropherogram of the sample.

[0101] In an analogous manner, the PCR protocol was applied to determine the PCR efficiency of a set of reference genes which were selected as a reference standard for quantification. In the present invention, the mean value of five such reference genes was determined: (1) cyclophilin B, using the specific primers 5'-ACTGAAGCACTACGGGC-CTG-3' and 5'-AGCCGTTGGTGCTTTGCC-3' except for MgCl₂ (an additional 1 mM was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 87° C. with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band of the expected size (62 bp). (2) Ribosomal protein S9 (RPS9), using the specific primers 5'-GGTCAAATTTACCCTG-GCCA-3' and 5'-TCTCATCAAGCGTCAGCAGTTC-3' (exception: additional 1 mM MgCl₂ was added instead of 3 mM). Melting curve analysis revealed a single peak at approximately 85° C. with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (62 bp). (3) beta-actin, using the specific primers 5'-TGGAACGGTGAAGGTGACA-3' and 5'-GGCAAGGGACTTCTGTAA-3'. Melting curve analysis revealed a single peak at approximately 87° C. with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (142 bp). (4) GAPDH, using the specific primers 5'-CGT-CATGGGTGTGAACCATG-3' and 5'-GCTAAGCAGTTG-GTGGTGCAG-3'. Melting curve analysis revealed a single peak at approximately 83° C. with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (81 bp). (5) Transferrin receptor

TRR, using the specific primers 5'-GTCGCTGGTCAGT-TCGTGATT-3' and 5'-AGCAGTTGGCTGTTGTAC-CTCTC-3'. Melting curve analysis revealed a single peak at approximately 83° C. with no visible primer dimers. Agarose gel analysis of the PCR product showed one single band with the expected size (80 bp).

[0102] For calculation of the values, first the logarithm of the cDNA concentration was plotted against the threshold cycle number C_t for human MAGUIN-1 and human MAGUIN-2, respectively, and the five reference standard genes. The slopes and the intercepts of the standard curves (i.e. linear regressions) were calculated for all genes. In a second step, cDNAs from temporal cortex and frontal cortex, and from hippocampus and frontal cortex, for human MAGUIN-1 and human MAGUIN-2, respectively, were analyzed in parallel and normalized to cyclophilin B. The C_t values were measured and converted to ng total brain cDNA using the corresponding standard curves:

$$100((C_t \text{ value} - \text{intercept}) / \text{slope}) [\text{ng total brain cDNA}]$$

[0103] The values for temporal cortex and frontal cortex of human MAGUIN-1 and human MAGUIN-2 cDNAs, and the values for hippocampus and frontal cortex of human MAGUIN-1 and human MAGUIN-2 cDNAs, respectively, were normalized to cyclophilin B, and the ratios were calculated using the following formulas:

$$\text{Ratio} = \frac{\text{human MAGUIN-1 (MAGUIN-2) temporal [ng]} / \text{cyclophilin B temporal [ng]}}{\text{human MAGUIN-1 (MAGUIN-2) frontal [ng]} / \text{cyclophilin B frontal [ng]}}$$

$$\text{Ratio} = \frac{\text{human MAGUIN-1 (MAGUIN-2) hippocampus [ng]} / \text{cyclophilin B hippocampus [ng]}}{\text{human MAGUIN-1 (MAGUIN-2) frontal [ng]} / \text{cyclophilin B frontal [ng]}}$$

[0104] In a third step, the set of reference standard genes was analyzed in parallel to determine the mean average value of the temporal to frontal ratios, and of the hippocampal to frontal ratios, respectively, of expression levels of the reference standard genes for each individual brain sample. As cyclophilin B was analyzed in step 2 and step 3, and the ratio from one gene to another gene remained constant in different runs, it was possible to normalize the values for human MAGUIN-1 and human MAGUIN-2 to the mean average value of the set of reference standard genes instead of normalizing to one single gene alone. The calculation was performed by dividing the ratio shown above by the deviation of cyclophilin B from the mean value of all housekeeping genes. The results of such quantitative RT-PCR analysis for the human MAGUIN-1 gene are shown in FIG. 3 and 4 and for the human MAGUIN-2 gene in FIG. 5 and 6.

[0105] (v) Sequence Analysis

[0106] Searching the EST database of the GenBank database for sequence similarities to the identified differentially expressed human cDNA fragment, SEQ ID NO. 7, as stated in the present invention, it was found that SEQ ID NO. 7 was identical to portions of the human EST sequences ai817268

and bf115709, (shown in **FIG. 17**). These human ESTs showed high homology to rat (*Rattus norvegicus*) MAGUIN-1. Aligning human ESTs in addition to the identified expressed SEQ ID NO. 7, a complete EST cluster representing the human MAGUIN-1 cDNA, SEQ ID NO. 5, was constructed. The amino acid sequence of a large open reading frame with the potential to encode a protein of 1034 amino acid residues was deduced (SEQ ID NO. 1). The human MAGUIN-1 protein, as denoted herein, is highly homologous to the rat MAGUIN-1 protein. In addition, it encodes a protein (SEQ ID NO. 1) harboring a number of structurally and functionally important domains. One SAM, one PDZ, and one PH domain are located from amino acid residues 8 to 75 (SAM), amino acid residues 156 to 296 (PDZ), and amino acid residues 572 to 667 (PH) (refer to **FIG. 7**).

[0107] (vi) Immunohistochemistry:

[0108] For immunofluorescence staining of Maguin-1 in human brain, frozen sections were prepared from post-mortem pre-central gyrus of a donor person (Cryostat Leica

CM3050S) and fixed in acetone for 10 min. After washing in PBS, the sections were pre-incubated with blocking buffer (10% normal goat serum, 0.2% Triton X-100 in PBS) for 30 min, and then incubated with affinity-purified rabbit anti-Maguin-1 antisera (1:20-1:50 diluted in blocking buffer, custom-made by Davids Biotechnologie, Regensburg) overnight at 4° C. After rinsing three times in 0.2% Triton X-100/PBS, the sections were incubated with FITC-conjugated goat anti-rabbit IgG (1:150 diluted in 1% BSA/PBS) for 2 hours at room temperature, and then again washed in PBS. Staining of the nuclei was performed by incubation of the sections with 5 μ M DAPI in PBS for 3 min (blue signal). In order to block the autofluorescence of lipofuscin in human brain, the sections were treated with 1% Sudan Black B in 70% ethanol for 2-10 min at room temperature, sequentially dipped in 70% ethanol, destained water and PBS. The sections were coverslipped by 'Vectashield mounting medium' (Vector Laboratories, Burlingame, Calif.) and observed under an inverted microscope (IX81, Olympus Optical). The digital images were captured with the appropriate software (AnalySiS, Olympus Optical).

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 24

<210> SEQ ID NO 1

<211> LENGTH: 1034

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```
Met Ala Leu Ile Met Glu Pro Val Ser Lys Trp Ser Pro Ser Gln Val
 1             5             10             15

Val Asp Trp Met Lys Gly Leu Asp Asp Cys Leu Gln Gln Tyr Ile Lys
      20             25             30

Asn Phe Glu Arg Glu Lys Ile Ser Gly Asp Gln Leu Leu Arg Ile Thr
 35             40             45

His Gln Glu Leu Glu Asp Leu Gly Val Ser Arg Ile Gly His Gln Glu
 50             55             60

Leu Ile Leu Glu Ala Val Asp Leu Leu Cys Ala Leu Asn Tyr Gly Leu
 65             70             75             80

Glu Thr Glu Asn Leu Lys Thr Leu Ser His Lys Leu Asn Ala Ser Ala
      85             90             95

Lys Asn Leu Gln Asn Phe Ile Thr Gly Arg Arg Arg Ser Gly His Tyr
 100            105            110

Asp Gly Arg Thr Ser Arg Lys Leu Pro Asn Asp Phe Leu Thr Ser Val
 115            120            125

Val Asp Leu Ile Gly Ala Ala Lys Ser Leu Leu Ala Trp Leu Asp Arg
 130            135            140

Ser Pro Phe Ala Ala Val Thr Asp Tyr Ser Val Thr Arg Asn Asn Val
 145            150            155            160

Ile Gln Leu Cys Leu Glu Leu Thr Thr Ile Val Gln Gln Asp Cys Thr
 165            170            175

Val Tyr Glu Thr Glu Asn Lys Ile Leu His Val Cys Lys Thr Leu Ser
 180            185            190

Gly Val Cys Asp His Ile Ile Ser Leu Ser Ser Asp Pro Leu Val Ser
```

-continued

195					200					205					
Gln	Ser	Ala	His	Leu	Glu	Val	Ile	Gln	Leu	Ala	Asn	Ile	Lys	Pro	Ser
210						215					220				
Glu	Gly	Leu	Gly	Met	Tyr	Ile	Lys	Ser	Thr	Tyr	Asp	Gly	Leu	His	Val
225					230					235					240
Ile	Thr	Gly	Thr	Thr	Glu	Asn	Ser	Pro	Ala	Asp	Arg	Cys	Lys	Lys	Ile
				245					250					255	
His	Ala	Gly	Asp	Glu	Val	Ile	Gln	Val	Asn	His	Gln	Thr	Val	Val	Gly
			260					265					270		
Trp	Gln	Leu	Lys	Asn	Leu	Val	Asn	Ala	Leu	Arg	Glu	Asp	Pro	Ser	Gly
	275						280					285			
Val	Ile	Leu	Thr	Leu	Lys	Lys	Arg	Pro	Gln	Ser	Met	Leu	Thr	Ser	Ala
290						295					300				
Pro	Ala	Leu	Leu	Lys	Asn	Met	Arg	Trp	Lys	Pro	Leu	Ala	Leu	Gln	Pro
305					310					315					320
Leu	Ile	Pro	Arg	Ser	Pro	Thr	Ser	Ser	Val	Ala	Thr	Pro	Ser	Ser	Thr
				325					330					335	
Ile	Ser	Thr	Pro	Thr	Lys	Arg	Asp	Ser	Ser	Ala	Leu	Gln	Asp	Leu	Tyr
			340					345					350		
Ile	Pro	Pro	Pro	Pro	Ala	Glu	Pro	Tyr	Ile	Pro	Arg	Asp	Glu	Lys	Gly
	355						360					365			
Asn	Leu	Pro	Cys	Glu	Asp	Leu	Arg	Gly	His	Met	Val	Gly	Lys	Pro	Val
370						375					380				
His	Lys	Gly	Ser	Glu	Ser	Pro	Asn	Ser	Phe	Leu	Asp	Gln	Glu	Tyr	Arg
385					390					395					400
Lys	Arg	Phe	Asn	Ile	Val	Glu	Glu	Asp	Thr	Val	Leu	Tyr	Cys	Tyr	Glu
			405					410						415	
Tyr	Glu	Lys	Gly	Arg	Ser	Ser	Ser	Gln	Gly	Arg	Arg	Glu	Ser	Thr	Pro
			420					425					430		
Thr	Tyr	Gly	Lys	Leu	Arg	Pro	Ile	Ser	Met	Pro	Val	Glu	Tyr	Asn	Trp
	435						440					445			
Val	Gly	Asp	Tyr	Glu	Asp	Pro	Asn	Lys	Met	Lys	Arg	Asp	Ser	Arg	Arg
450						455					460				
Glu	Asn	Ser	Leu	Leu	Arg	Tyr	Met	Ser	Asn	Glu	Lys	Ile	Ala	Gln	Glu
465					470					475					480
Glu	Tyr	Met	Phe	Gln	Arg	Asn	Ser	Lys	Lys	Asp	Thr	Gly	Lys	Lys	Ser
			485						490					495	
Lys	Lys	Lys	Gly	Asp	Lys	Ser	Asn	Ser	Pro	Thr	His	Tyr	Ser	Leu	Leu
			500					505					510		
Pro	Ser	Leu	Gln	Met	Asp	Ala	Leu	Arg	Gln	Asp	Ile	Met	Gly	Thr	Pro
	515						520					525			
Val	Pro	Glu	Thr	Thr	Leu	Tyr	His	Thr	Phe	Gln	Gln	Ser	Ser	Leu	Gln
530						535					540				
His	Lys	Ser	Lys	Lys	Lys	Asn	Lys	Gly	Pro	Ile	Ala	Gly	Lys	Ser	Lys
545					550					555					560
Arg	Arg	Ile	Ser	Cys	Lys	Asp	Leu	Gly	Arg	Gly	Asp	Cys	Glu	Gly	Trp
				565					570					575	
Leu	Trp	Lys	Lys	Lys	Asp	Ala	Lys	Ser	Tyr	Phe	Ser	Gln	Lys	Trp	Lys
			580					585					590		
Lys	Tyr	Trp	Phe	Val	Leu	Lys	Asp	Ala	Ser	Leu	Tyr	Trp	Tyr	Ile	Asn
	595						600					605			

-continued

Glu	Glu	Asp	Glu	Lys	Ala	Glu	Gly	Phe	Ile	Ser	Leu	Pro	Glu	Phe	Lys	610	615	620
Ile	Asp	Arg	Ala	Ser	Glu	Cys	Arg	Lys	Lys	Tyr	Ala	Phe	Lys	Ala	Cys	625	630	635
His	Pro	Lys	Ile	Lys	Ser	Phe	Tyr	Phe	Ala	Ala	Glu	His	Leu	Asp	Asp	645	650	655
Met	Asn	Arg	Trp	Leu	Asn	Arg	Ile	Asn	Met	Leu	Thr	Ala	Gly	Tyr	Ala	660	665	670
Glu	Arg	Glu	Arg	Ile	Lys	Gln	Glu	Gln	Asp	Tyr	Trp	Ser	Glu	Ser	Asp	675	680	685
Lys	Glu	Glu	Ala	Asp	Thr	Pro	Ser	Thr	Pro	Lys	Gln	Asp	Ser	Pro	Pro	690	695	700
Pro	Pro	Tyr	Asp	Thr	Tyr	Pro	Arg	Pro	Pro	Ser	Met	Ser	Cys	Ala	Ser	705	710	715
Pro	Tyr	Val	Glu	Ala	Lys	His	Ser	Arg	Leu	Ser	Ser	Thr	Glu	Thr	Ser	725	730	735
Gln	Ser	Gln	Ser	Ser	His	Glu	Glu	Phe	Arg	Gln	Glu	Val	Thr	Gly	Ser	740	745	750
Ser	Ala	Val	Ser	Pro	Ile	Arg	Lys	Thr	Ala	Ser	Gln	Arg	Arg	Ser	Trp	755	760	765
Gln	Asp	Leu	Ile	Glu	Thr	Pro	Leu	Thr	Ser	Ser	Gly	Leu	His	Tyr	Leu	770	775	780
Gln	Thr	Leu	Pro	Leu	Glu	Asp	Ser	Val	Phe	Ser	Asp	Ser	Ala	Ala	Ile	785	790	795
Ser	Pro	Glu	His	Arg	Arg	Gln	Ser	Thr	Leu	Pro	Thr	Gln	Lys	Cys	His	805	810	815
Leu	Gln	Asp	His	Tyr	Gly	Pro	Tyr	Pro	Leu	Ala	Glu	Ser	Glu	Arg	Met	820	825	830
Gln	Val	Leu	Asn	Gly	Asn	Gly	Gly	Lys	Pro	Arg	Ser	Phe	Thr	Leu	Pro	835	840	845
Arg	Asp	Ser	Gly	Phe	Asn	His	Cys	Cys	Leu	Asn	Ala	Pro	Val	Ser	Ala	850	855	860
Cys	Asp	Pro	Gln	Asp	Asp	Val	Gln	Pro	Pro	Glu	Val	Glu	Glu	Glu	Glu	865	870	875
Glu	Glu	Glu	Glu	Glu	Glu	Gly	Glu	Ala	Ala	Gly	Glu	Asn	Ile	Gly	Glu	885	890	895
Lys	Ser	Glu	Ser	Arg	Glu	Glu	Lys	Leu	Gly	Asp	Ser	Leu	Gln	Asp	Leu	900	905	910
Tyr	Arg	Ala	Leu	Glu	Gln	Ala	Ser	Leu	Ser	Pro	Leu	Gly	Glu	His	Arg	915	920	925
Ile	Ser	Thr	Lys	Met	Glu	Tyr	Lys	Leu	Ser	Phe	Ile	Lys	Arg	Cys	Asn	930	935	940
Asp	Pro	Val	Met	Asn	Glu	Lys	Leu	His	Arg	Leu	Arg	Ile	Leu	Lys	Ser	945	950	955
Thr	Leu	Lys	Ala	Arg	Glu	Gly	Glu	Val	Ala	Ile	Ile	Asp	Lys	Val	Leu	965	970	975
Asp	Asn	Pro	Asp	Leu	Thr	Ser	Lys	Glu	Phe	Gln	Gln	Trp	Lys	Gln	Met	980	985	990
Tyr	Leu	Asp	Leu	Phe	Leu	Asp	Ile	Cys	Gln	Asn	Thr	Thr	Ser	Asn	Asp	995	1000	1005

-continued

```

Pro Leu Ser Ile Ser Ser Glu Val Asp Val Ile Thr Ser Ser Leu Ala
1010                      1015                      1020

His Thr His Ser Tyr Ile Glu Thr His Val
1025                      1030

<210> SEQ ID NO 2
<211> LENGTH: 948
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Phe Ile Gly Arg Glu Ser Glu Gln Ile Asp Asn Ala Met Ile Asn Ala
 1             5             10             15

Cys Ile Asp Ser Glu Gln Glu Asn Cys Glu Phe His Met Ala Asn Met
 20            25            30

Ala Gly Ile Asn Pro Arg Thr Glu Ile Asn Leu Glu Asn Gly Thr His
 35            40            45

Ala Ala Met Ala Leu Ile Met Glu Pro Val Ser Lys Trp Ser Pro Ser
 50            55            60

Gln Val Val Asp Trp Met Lys Gly Leu Asp Asp Cys Leu Gln Gln Tyr
 65            70            75            80

Ile Lys Asn Phe Glu Arg Glu Lys Ile Ser Gly Asp Gln Leu Leu Arg
 85            90            95

Ile Thr His Gln Glu Leu Glu Asp Leu Gly Val Ser Arg Ile Gly His
100            105            110

Gln Glu Leu Ile Leu Glu Ala Val Asp Leu Leu Cys Ala Leu Asn Tyr
115            120            125

Gly Leu Glu Thr Glu Asn Leu Lys Thr Leu Ser His Lys Leu Asn Ala
130            135            140

Ser Ala Lys Asn Leu Gln Asn Phe Ile Thr Gly Arg Arg Arg Ser Gly
145            150            155            160

His Tyr Asp Gly Arg Thr Ser Arg Lys Leu Pro Asn Asp Phe Leu Thr
165            170            175

Ser Val Val Asp Leu Ile Gly Ala Ala Lys Ser Leu Leu Ala Trp Leu
180            185            190

Asp Arg Ser Pro Phe Ala Ala Val Thr Asp Tyr Ser Val Thr Arg Asn
195            200            205

Asn Val Ile Gln Leu Cys Leu Glu Leu Thr Thr Ile Val Gln Gln Asp
210            215            220

Cys Thr Val Tyr Glu Thr Glu Asn Lys Ile Leu His Val Cys Lys Thr
225            230            235            240

Leu Ser Gly Val Cys Asp His Ile Ile Ser Leu Ser Ser Asp Pro Leu
245            250            255

Val Ser Gln Ser Ala His Leu Glu Val Ile Gln Leu Ala Asn Ile Lys
260            265            270

Pro Ser Glu Gly Leu Gly Met Tyr Ile Lys Ser Thr Tyr Asp Gly Leu
275            280            285

His Val Ile Thr Gly Thr Thr Glu Asn Ser Pro Ala Asp Arg Cys Lys
290            295            300

Lys Ile His Ala Gly Asp Glu Val Ile Gln Val Asn His Gln Thr Val
305            310            315            320

Val Gly Trp Gln Leu Lys Asn Leu Val Asn Ala Leu Arg Glu Asp Pro
325            330            335

```

-continued

Ser Gly Val	Ile Leu Thr	Leu Lys	Lys Arg Pro	Gln Ser Met	Leu Thr
340		345		350	
Ser Ala Pro	Ala Leu Leu	Lys Asn Met	Arg Trp Lys	Pro Leu Ala	Leu
355		360		365	
Gln Pro Leu	Ile Pro Arg	Ser Pro Thr	Ser Ser Val	Ala Thr Pro	Ser
370		375		380	
Ser Thr Ile	Ser Thr Pro	Thr Lys Arg	Asp Ser Ser	Ala Leu Gln	Asp
385		390		395	400
Leu Tyr Ile	Pro Pro Pro	Pro Ala Glu	Pro Tyr Ile	Pro Arg Asp	Glu
	405		410		415
Lys Gly Asn	Leu Pro Cys	Glu Asp Leu	Arg Gly His	Met Val Gly	Lys
	420		425		430
Pro Val His	Lys Gly Ser	Glu Ser Pro	Asn Ser Phe	Leu Asp Gln	Glu
	435		440		445
Tyr Arg Lys	Arg Phe Asn	Ile Val Glu	Glu Asp Thr	Val Leu Tyr	Cys
450		455		460	
Tyr Glu Tyr	Glu Lys Gly	Arg Ser Ser	Ser Gln Gly	Arg Arg Glu	Ser
465		470		475	480
Thr Pro Thr	Tyr Gly Lys	Leu Arg Pro	Ile Ser Met	Pro Val Glu	Tyr
	485		490		495
Asn Trp Val	Gly Asp Tyr	Glu Asp Pro	Asn Lys Met	Lys Arg Asp	Ser
	500		505		510
Arg Arg Glu	Asn Ser Leu	Leu Arg Tyr	Met Ser Asn	Glu Lys Ile	Ala
	515		520		525
Gln Glu Glu	Tyr Met Phe	Gln Arg Asn	Ser Lys Lys	Asp Thr Gly	Lys
530		535		540	
Lys Ser Lys	Lys Lys Gly	Asp Lys Ser	Asn Ser Pro	Thr His Tyr	Ser
545		550		555	560
Leu Leu Pro	Ser Leu Gln	Met Asp Ala	Leu Arg Gln	Asp Ile Met	Gly
	565		570		575
Thr Pro Val	Pro Glu Thr	Thr Leu Tyr	His Thr Phe	Gln Gln Ser	Ser
	580		585		590
Leu Gln His	Lys Ser Lys	Lys Lys Asn	Lys Gly Pro	Ile Ala Gly	Lys
	595		600		605
Ser Lys Arg	Arg Ile Ser	Cys Lys Asp	Leu Gly Arg	Gly Asp Cys	Glu
610		615		620	
Gly Trp Leu	Trp Lys Lys	Asp Ala Lys	Ser Tyr Phe	Ser Gln Lys	
625		630		635	640
Trp Lys Lys	Tyr Trp Phe	Val Leu Lys	Asp Ala Ser	Leu Tyr Trp	Tyr
	645		650		655
Ile Asn Glu	Glu Asp Glu	Lys Ala Glu	Gly Phe Ile	Ser Leu Pro	Glu
	660		665		670
Phe Lys Ile	Asp Arg Ala	Ser Glu Cys	Arg Lys Lys	Tyr Ala Phe	Lys
	675		680		685
Ala Cys His	Pro Lys Ile	Lys Ser Phe	Tyr Phe Ala	Ala Glu His	Leu
	690		695		700
Asp Asp Met	Asn Arg Trp	Leu Asn Arg	Ile Asn Met	Leu Thr Ala	Gly
705		710		715	720
Tyr Ala Glu	Arg Glu Arg	Ile Lys Gln	Glu Gln Asp	Tyr Trp Ser	Glu
	725		730		735

-continued

Ser	Asp	Lys	Glu	Glu	Ala	Asp	Thr	Pro	Ser	Thr	Pro	Lys	Gln	Asp	Ser
			740					745					750		
Pro	Pro	Pro	Pro	Tyr	Asp	Thr	Tyr	Pro	Arg	Pro	Pro	Ser	Met	Ser	Cys
			755				760					765			
Ala	Ser	Pro	Tyr	Val	Glu	Ala	Lys	His	Ser	Arg	Leu	Ser	Ser	Thr	Glu
			770				775				780				
Thr	Ser	Gln	Ser	Gln	Ser	Ser	His	Glu	Glu	Phe	Arg	Gln	Glu	Val	Thr
			785			790				795					800
Gly	Ser	Ser	Ala	Val	Ser	Pro	Ile	Arg	Lys	Thr	Ala	Ser	Gln	Arg	Arg
				805					810					815	
Ser	Trp	Gln	Asp	Leu	Ile	Glu	Thr	Pro	Leu	Thr	Ser	Ser	Gly	Leu	His
			820					825					830		
Tyr	Leu	Gln	Thr	Leu	Pro	Leu	Glu	Asp	Ser	Val	Phe	Ser	Asp	Ser	Ala
			835				840					845			
Ala	Ile	Ser	Pro	Glu	His	Arg	Arg	Gln	Ser	Thr	Leu	Pro	Thr	Gln	Lys
			850			855					860				
Cys	His	Leu	Gln	Asp	His	Tyr	Gly	Pro	Tyr	Pro	Leu	Ala	Glu	Ser	Glu
			865			870				875					880
Arg	Met	Gln	Val	Leu	Asn	Gly	Asn	Gly	Gly	Lys	Pro	Arg	Ser	Phe	Thr
				885					890					895	
Leu	Pro	Arg	Asp	Ser	Gly	Phe	Asn	His	Cys	Cys	Leu	Asn	Ala	Pro	Val
			900					905					910		
Ser	Ala	Cys	Asp	Pro	Gln	Asp	Asp	Val	Gln	Pro	Pro	Glu	Val	Glu	Glu
			915				920					925			
Glu	Glu	Glu	Glu	Glu	Glu	Glu	Glu	Gly	Glu	Ala	Ala	Gly	Glu	Asn	Ile
			930				935					940			
Gly	Glu	Lys	Ser												
			945												

<210> SEQ ID NO 3

<211> LENGTH: 3105

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

atggctctga taatggaacc ggtgagcaaa tggctctccga gtcaagtagt ggactggatg	60
aaaggtcttg atgactgttt gcagcagtat attaagaact ttgagaggga gaagatcagt	120
ggggaccagc tgctgcgcac tacacatcag gagctagaag atctgggggt cagccgcatt	180
ggccatcagg aactgatctt ggaagcagtt gaccttctgt gtgcattgaa ttatggcttg	240
gaaacagaaa atctaaaaac cttttctcac aagttgaatg catctgcaa aaatctgcag	300
aattttataa caggaaggag aaggagtggc cattatgatg ggaggaccag ccgaaaattg	360
ccaaacgact ttctgacctc agttgtggat ctgattggag cagccaagag tctgcttgcc	420
tggttggaac ggtcaccatt tgctgctgtg acagactatt cagttacaag aaataatgtc	480
atacaactct gcotggagtt aacaacaatt gtgcaacagg attgtactgt atatgaaaca	540
gagaataaaa ttcttcacgt gtgtaaaact ctttctggag tctgtgacca catcatatcc	600
ctgtcgtcag atcctctggt ttcacagtct gctcacctgg aagtgttca actggcaaac	660
attaaaccaa gcgaagggtc gggatatgtat attaaatcta catatgatgg cctccatgta	720
attactggaa ccacagaaaa ttcacctgca gatcgggtgca agaaaatcca tgctggcgat	780

-continued

gaagtgattc aagttaatca tcagactgtg gtggggtggc agttgaaaaa tttggtgaat	840
gcactacgag aggacccgag tgggtgttatc ttaactttga aaaagcgacc tcagagcatg	900
cttacctcag caccagcttt actgaaaaat atgagatgga agcccttgc tctgcagcct	960
cttataccta gaagtccac aagcagcgtt gccacgcctt ccagcaccat cagtacaccc	1020
acaaaaagag acagttctgc cctccaggat ctctacattc cccctcctcc tgcagaacca	1080
tatatccca gggatgaaaa aggaacacct ccttgtgaag acctcagagg acatatggtg	1140
ggcaagccag tgcataaggg atctgaatca ccaattcat ttctggatca ggaatatcga	1200
aagagattta atattgtcga agaagatact gtcttatatt gctatgaata tgaanaagga	1260
agatcaagta gtcaaggaag acgagaaagc accccaactt atggcaagct acgacctata	1320
tctatgccag tggatataa ttgggtgggg gactatgaag atccaaataa gatgaagaga	1380
gatatgagaa gagaaaactc tctacttcgg tatatgagca atgaaaagat tgctcaagaa	1440
gaatacatgt ttcagagaaa cagcaaaaag gacacaggga agaagtcaa aaagaagggt	1500
gataagagta atagcccaac tcactattca ttgctaccta gtttacaat ggatgcactg	1560
agacaagaca tcatgggcac tcctgtgccca gagaccacac tataccatac atttcagcag	1620
tcctcactgc agcacaaatc aaagaagaaa aacaaaggtc ctatagcagg caagagcaaa	1680
agacgaattt cttgcaaaa tcttgccgtt ggtgactgtg agggctggct ttggaaaaag	1740
aaagatgcca agagttactt ttcacagaaa tggaaaaat attggtttgt cctaaaggat	1800
gcaccccttt attgtatat taatgaggag gatgaaaaag cagaaggatt cattagcctg	1860
cctgaattta aaattgatag agccagtga tgcgcgcaaaa aatatgcatt caaagcctgt	1920
catcctaaaa tcaaaagctt ttattttgct gctgaacatc ttgatgatat gaacagggtg	1980
cttaacagaa ttaatatgct gactgcagga tatgcagaaa gagagaggat taagcaggaa	2040
caagattact ggagtgagag tgacaaggaa gaagcagata ctccatcaac accaaaacaa	2100
gatagccctc cacccccata tgatacatc ccacgacctc cctcgatgag ttgcgccagt	2160
ccttatgttg aagcaaaaac tagccgactt tcctccacgg agacttctca gtctcagtct	2220
tctcatgagg agtttcgcca ggaagtaact gggagcagtg cagtgtctcc cattcgcaag	2280
acagccagtc agcgccgctc ctggcaggat ttaattgaga cgccactgac aagttcaggc	2340
ttacactatc ttcagactct gccctggag gattctgtct tctctgactc cgcggccatc	2400
tcccagagc acaggcggca gtctaccctg ccaactcaga aatgccacct gcaggatcac	2460
tatgggcat accccttagc tgagagtgag aggatgcaag tgctaaatgg aaatgggggc	2520
aagcctcgaa gttttactt gcctcgagat agcgggttca accattgtct tctgaatgct	2580
ccagttagtg cctgtgacct acaggatgac gtgcaacccc cagagggtga ggaagaggag	2640
gaggaggagg aggaggaagg ggaggcagca ggggaaaaa taggagaaaa aagtgaagc	2700
agagaagaaa agttaggaga ctcatgcaa gatttataca gggcactgga gcaggccagt	2760
ctgtcaccac taggagaaca tcgtatttca accaagatgg aatacaagct atcatttata	2820
aaaagatgta atgacctgt aatgaatgaa aaactacacc ggctgagaat tctcaaaagc	2880
actttaaagg ccagagaagg ggaagtagcc attatcgata aagtcctaga caatccagac	2940
ttgacatcta aagaattcca acaatggaag cagatgtacc tcgacctttt cttggatata	3000
tgtcaaaata ccacctcaa tgacctctg agtatttctt ctgaagtaga tgtaatcact	3060

-continued

tcctctctag cacacactca ttcatacatt gaaacgcatg totaa 3105

<210> SEQ ID NO 4
 <211> LENGTH: 2683
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

atggctctga taatggaacc ggtgagcaaa tggctctccga gtcaagtagt ggactggatg 60
 aaaggtcttg atgactgttt gcagcagtat attaagaact ttgagaggga gaagatcagt 120
 ggggaccagc tgctgcgcac tacacatcag gagctagaag atctgggggt cagccgcatt 180
 ggccatcagg aactgatctt ggaagcagtt gaccttctgt gtgcattgaa ttatggcttg 240
 gaaacagaaa atctaaaaac cttttctcac aagttgaatg catctgcaa aaatctgcag 300
 aattttataa caggaaggag aaggagtggc cattatgatg ggaggaccag ccgaaaattg 360
 ccaaacgact ttctgacctc agttgtggat ctgattggag cagccaagag tctgcttgcc 420
 tgggtggaca ggtcaccatt tgctgctgtg acagactatt cagttacaag aaataatgtc 480
 atacaactct gcctggagtt aacaacaatt gtgcaacagg attgtactgt atatgaaca 540
 gagaataaaa ttcttcacgt gtgtaaaact ctttctggag tctgtgacca catcatatcc 600
 ctgtcgtcag atcctctggt ttcacagtct gctcacctgg aagtattca gctggcaaac 660
 attaaaccaa gcgaagggtt gggatatgat attaaatcta catatgatgg cctccatgta 720
 attactggaa ccacagaaaa ttcacctgca gatcggtgca agaaaatcca tgctggcgat 780
 gaagtgattc aagttaatca tcagactgtg gtgggtggc agttgaaaaa ttggtgaat 840
 gcactacgag aggacccgag tgggtgtatc ttaactttga aaaagcgacc tcagagcatg 900
 cttacctcag caccagcttt actgaaaaat atgagatgga agcccttgc tctgcagcct 960
 cttataccta gaagtccac aagcagcgtt gccacgcctt ccagcaccat cagtacacc 1020
 accaaaagag acagttctgc cctccaggat ctctacattc cccctcctcc tgcagaacca 1080
 tataattcca gggatgaaaa aggaacacct cttgtgaag acctcagagg acatatggtg 1140
 ggcaagccag tgcataaggg atctgaatca ccaaattcat ttctggatca ggaatatcga 1200
 aagagattta atattgtcga agaagatact gtottatatt gctatgaata tgaaaaagga 1260
 agatcaagta gtcaaggga acgagaaagc accccaactt atggcaagct acgacctata 1320
 tctatgccag tggaatataa ttgggtgggg gactatgaag atccaataa gatgaagaga 1380
 gatagtagaa gagaaaactc tctacttcgg tatatgagca atgaaaagat tgctcaagaa 1440
 gaatacatgt ttcagagaaa cagcaaaaag gacacaggga agaagtcaaa aaagaagggt 1500
 gataagagta atagcccaac tcaatttca ttgctaccta gtttacaaat ggatgcactg 1560
 agacaagaca tcattggcac tctgtgcca gagaccacac tataccatac atttcagcag 1620
 tcctcactgc agcacaaatc aaagaagaaa aacaaaggtc ctatagcagg caagagcaaa 1680
 agacgaattt cttgcaaga tcttgccgt ggtgactgtg agggctggct ttggaaaaag 1740
 aaagatgcga agagttactt ttcacagaaa tggaaaaaat attggtttgt cctaaaggat 1800
 gcaccccttt attggtatat taatgaggag gatgaaaaag cagaaggatt cattagcctg 1860
 cctgaattta aaattgatag agccagtga tgccgcaaaa aatatgcatt caaagcctgt 1920
 catcctaaaa tcaaaagctt ttattttgct gctgaacatc ttgatgatat gaacaggtgg 1980

-continued

cttaacagaa ttaatatgct gactgcagga tatgcagaaa gagagaggat taagcaggaa	2040
caagattact ggagtgcagc tgacaaggaa gaagcagata ctccatcaac accaaaacaa	2100
gatagccctc cacccccata tgatacatac ccacgacctc cctcgatgag ttgcgccagt	2160
ccttatgtgg aagcaaaaca tagccgactt tcctccacgg agactttctc gtctcagtct	2220
tctcatgagg agtttcgcca ggaagtaact gggagcagtg cagtgtctcc cattcgcaag	2280
acagccagtc agcgccgctc ctggcaggat ttaattgaga cgccactgac aagttcaggc	2340
ttacactatc ttcagactct gccctggag gattctgtct tctctgactc cgcggccatc	2400
tccccagagc acaggcggga gtctaccctg ccaactcaga aatgccacct gcaggatcac	2460
tatgggcat accccttagc tgagagtgc aggatgcaag tgctaaatgg aaatgggggc	2520
aagcctcgaa gttttactct gcctcgagat agcgggttca accattgctg tctgaatgct	2580
ccagttagtg cctgtgacct acaggatgac gtgcaacccc cagaggtgga ggaagaggag	2640
gaggaggagg aggaggaagg ggaggcagca ggggaaaaca tag	2683

<210> SEQ ID NO 5

<211> LENGTH: 5749

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: cDNA of human Maguin-1

<400> SEQUENCE: 5

cgggcagcta gtcgtgctcg gggcttcaact cccgcgcgtg aggcgagcgg gcaagttggc	60
tgagggcgtg cggcagaggc tgcttcctc gccgacgcga cccctcagca actcaagcta	120
tgaactgaag ctccctaggg acggagaccg gagcggagcg gcggaggcag cagcagcagc	180
agcagcagca gcagcagcag cagccgcccgc cgccgcccgc ttagcgggaa ctgagcagac	240
ccggcgcgga gccacgactc ctgcacgttt acctccctgt cgccgttccct gccggcggtt	300
ggctaaaaga cgttacagcc gcgagacccg acacacaaaa gccgctttct ccgcgcccgc	360
cgcccaggga ggcgtcgggc agcaaggagc cccacctgag agcagctcgg gctgctgagt	420
tcgttttggt tctgagctct gcgctctgca cggaaccgac cccgtaccca tggctctgat	480
aatggaaccg gtgagcaaat ggtctccgag tcaagtagtg gactggatga aaggtcttga	540
tgactgtttg cagcagtata ttaagaactt tgagaggag aagatcagtg gggaccagct	600
gctgcgcatt acacatcagg agctagaaga tctgggggtc agccgcattg gccatcagga	660
actgatcttg gaagcagttg accttctgtg tgcattgaat tatggcttgg aaacagaaaa	720
tctaaaaacc ctttctcaca agttgaatgc atctgccaaa aatctgcaga attttataac	780
aggaaggaga aggagtggcc attatgatgg gaggaccagc cgaatttgc caaacgactt	840
tctgacctca gttgtggatc tgattggagc agccaagagt ctgcttgccct ggttgacag	900
gtcaccatth gctgctgtga cagactatc agttacaaga aataatgtca tacaactctg	960
cctggagtta acaacaattg tgcaacagga ttgtactgta tatgaaacag agaataaaat	1020
tcttcacgtg tgtaaaactc tttctggagt ctgtgaccac atcatatccc tgcgtcaga	1080
tcctctggtt tcacagtctg ctccactgga agtgattcaa ctggcaacaa ttaaaccaag	1140
cgaagggtg ggtatgtata taaatctac atatgatggc ctccatgtaa ttactggaac	1200
cacagaaaat tcacctgcag atcgggtgcaa gaaaatccat gctggcgatg aagtgattca	1260

-continued

agttaatcat cagactgtgg tggggtggca gttgaaaaat ttggtgaatg cactacgaga	1320
ggacccgagt ggtgttatct taactttgaa aaagcgacct cagagcatgc ttacctcagc	1380
accagcttta ctgaaaaata tgagatggaa gccccttgct ctgcagcctc ttatacctag	1440
aagtcccaca agcagcgttg ccacgccttc cagcaccatc agtacacca ccaaaagaga	1500
cagttctgcc ctccaggatc tctacattcc cctcctcct gcagaacat atattcccag	1560
ggatgaaaaa ggaaaccttc cttgtgaaga cctcagagga catatggtgg gcaagccagt	1620
gcataaggga tctgaatcac caaattcatt tctggatcag gaatacga agagatttaa	1680
tattgtcgaa gaagatactg tcttatattg ctatgaatat gaaaaaggaa gatcaagtag	1740
tcaaggaga cgagaaagca cccaactta tggcaagcta cgacctatat ctatgccagt	1800
ggaatataat tgggtggggg actatgaaga tccaaataag atgaagagag atagtagaag	1860
agaaaactct ctacttcggt atatgagcaa tgaagagatt gctcaagaag aatacatgtt	1920
tcagagaaac agcaaaaagg acacaggga gaagcaaaa aagaaggggtg ataagagtaa	1980
tagcccaact cactattcat tgctacctag ttacaaaatg gatgcactga gacaagacat	2040
catgggcact cctgtgccag agaccacact ataccataca tttcagcagt cctcactgca	2100
gcacaaatca aagaagaaaa acaaaggctc tatagcaggc aagagcaaaa gacgaatttc	2160
ttgcaaagat cttggccgtg gtgactgtga gggctggctt tggaaaaaga aagatgcgaa	2220
gagttacttt tcacagaaat ggaaaaata ttggtttgtc ctaaaggatg catcccttta	2280
ttggtatatt aatgaggagg atgaaaaagc agaaggattc attagcctgc ctgaatttaa	2340
aattgataga gccagtgaat gccgcaaaa atatgcattc aaagcctgtc atcctaaaat	2400
caaaagcttt tattttgctg ctgaacatct tgatgatatg aacagggtggc ttaacagaat	2460
taatatgctg actgcaggat atgcagaaag agagaggatt aagcaggaac aagattactg	2520
gagtgaagat gacaaggaag aagcagatac tccatcaaca ccaaaacaag atagccctcc	2580
accccatat gatacatacc cagcacctcc ctcgatgagt tgcgccagtc cttatgtgga	2640
agcaaaacat agccgacttt cctccacgga gacttctcag tctcagtcct ctcatgagga	2700
gtttcgccag gaagtaactg ggagcagtc agtgtctccc attcgcaaga cagccagtca	2760
gcgcgcgtcc tggcaggatt taattgagac gccactgaca agttcaggct tacactatct	2820
tcagactctg cccctggagg attctgtctt ctctgactcc gcggccatct cccagagca	2880
caggcggcag tctacctgc caactcagaa atgccacctg caggatcact atgggccata	2940
ccccttagct gagagtga ggatgcaagt gctaaatgga aatgggggca agcctcgaag	3000
ttttactctg cctcgagata gcgggttcaa ccattgctgt ctgaatgctc cagttagtgc	3060
ctgtgacca caggatgac tgcaaccccc agagggtggag gaagaggagg aggaggagga	3120
ggaggaaggg gaggcagcag gggaaaacat aggagaaaa agtgaaagca gagaagaaaa	3180
gttaggagac tcatgcaag atttatacag ggcactggag caggccagtc tgtcaccact	3240
aggagaacat cgtatttcaa ccaagatgga atacaagcta tcatttataa aaagatgtaa	3300
tgatcctgta atgaatgaaa aactacaccg gctgagaatt ctcaaaagca ctttaaaggc	3360
cagagaaggg gaagtagcca ttatcgataa agtcctagac aatccagact tgacatctaa	3420
agaattccaa caatggaagc agatgtacct cgaccttttc ttggatatct gtcaaaatac	3480
cacctcaaat gacctactga gtattttctt tgaagtagat gtaatcactt cctctctagc	3540

-continued

acacactcat tcatacattg aaacgcatgt ctaaatgtat tctgcttca gaccatctag	3600
tacctgctgg tactctgaac aagtatataa ggtagttttt atatcaatgt gtggaacact	3660
tgacaagcta tactttaatg ttaccaaact atatgaaaca aaccatatat ggtcacaata	3720
ccactatctt taatgagcat ttgtatatat tatatgcaac agtgcctcagc ttatgtttac	3780
catgtgcaaa atcaactgtc tttaatgact taaaattaac ttttgcaaac aattctaaat	3840
acaggtgggc ttcaagtagt aaaaccacaa aaggcagttt tctatctatg gtcactcttt	3900
ctccctttta gttaatttta tataaacaag acttcaaaag taaatcacat tttttcaggt	3960
gcagacatcc ttgtgggtgg gaaagaattt aaaccttttt tatatttatt aaaatgttct	4020
aagaattttc ttaaaccattg cacaagttt aatgctgtag ttttattttt gtgaaatgta	4080
gatgcgcata caagagctaa gcaaaataga agagcatcga cataagaaaa gttcaggtat	4140
ctaataattcg tcttaatatg ctattaactt gtgaaagcta agttaatgga aatattattc	4200
caaatctatg agaacacttg gtgtatcagg gcaaagcttt gtaagatgtt tttgtaacta	4260
agacccaaat tgaagataga gctgctttat tttcttggtt taaatcttcc tttatttttg	4320
tagtgatgag atgctgattg tgtacagaag aatttgagag gggattttta aaaactgact	4380
taacacaccc agaaggcag ctaacagcta tatatatata taaatttcag cccaaactca	4440
tgtttttaaa ctccaactct taaaagacaa caaggataaa actgaaatga atcaactttc	4500
cacttagttt ccaatttttc cctagtccac taattaaact taggtaatta tacttcaggt	4560
agggaaagtac aatatgttta gtttcaggct gatgtgtgtt ataaaaaaca aactgaaaa	4620
ataaaaatgt acttcccttc taaggagcaa gcagggtgatg gtcattcaaa gagatgtcac	4680
attgaattat gagagaaaca atttagagg ttttttcctg gcttcattgaa ttgttctata	4740
gagtggatga agtctaagga aaagtctctt tcatatatat ccattttata gcgtcttggt	4800
tttgaaagtg atcacagcat gaaaatgact gtgctgcttt ttagtgtctg gctgcataat	4860
gtacaagtca caatttgctg tttttttcag gaggagaaag ggaacctcct ttactattct	4920
atatcctaaa atctacttct aatcagcttt atactgttgc ctgtacagct cagtgaatgt	4980
actttcatct ttaagagttc agatatatgc cagtgaatat ttttgctgta gaggagaaag	5040
taaaaactcc acagcgggga tctttttctt tgcttttgaa accaccattg aatcactatc	5100
gttttgacga ctttgacaaa ctgtacagga gagtggcctt tctacagcac attttcagta	5160
atcctatatt tagtcaaat ggatgagaaa tcatgtatta atgtttgtat ggaatttttg	5220
gtccagtgtg atatttttat catttaaaaa gaactctatt tgtaaaaaa tttatttact	5280
gcattggatat tgacgcacat taaatttggt ggattttgta tatgtaaaa aaaaaaaaaa	5340
aaaaaaaaac aaaaacctc ttgtcctaaa atgaagtgtg cttgttaaca ggtgtttaga	5400
cttattgatg tttactagac caaatgtgta tgttcactta aaaatatatg tacctgatgg	5460
atgtgtcatg tttacagtg ccagggtgtg gcctgtaaac agcaagcagt tgacgggaag	5520
actagctctg ttgctactaa gcagctttta cttttgtaaa gtcagctctg ttgtttttaa	5580
tggtaaaaat taaactaatg aatttgacaa gactcgtggc tagcctagca tgaaagagac	5640
cttttaacac tatataatat ctgtacattt tattgcattc gtttcaaatc taggagagag	5700
gcagcactgt aaactgaagt caaataaatt cagctcttaa tgaatcctt	5749

-continued

<210> SEQ ID NO 6
<211> LENGTH: 4350
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: cDNA of human Maguin-2

<400> SEQUENCE: 6

gtgctcgggg cttcactccc gcgcgtgagg cgagcgggca agttggctga ggcgtgcgg	60
cagaggctgc ttccctcggc gacgcgaccc ctacgcaact caagctatga actgaagctc	120
cctagggacg gagaccggag cggagcggcg gaggcagcag cagcagcagc agcagcagca	180
gcagcagcag ccgcgcgcgc gcgcgcctta gcgggaactg agcagacccg gcgcggagcc	240
acgactcctg cacgtttacc tccctgtcgc cgttcctgcc ggcggttggc taaaagacgt	300
tacagccgcg agacccgaca cacaaaagcc gctttctccg cgccgcccg ccagggaggc	360
tgcggccagc aagggaaccc acctgagagc agctcgggct gctgagttcg tttgtgtct	420
gagctctgcg ctctgcacgg aaccgacccc gtacccatgg ctctgataat ggaaccggtg	480
agcaaattgt ctccgagtca agtagtggac tggatgaaag gtcttgatga ctgtttgcag	540
cagtatatta agaactttga gagggagaag atcagtggg accagctgct gcgcattaca	600
catcaggagc tagaagatct gggggtcagc cgcattggcc atcaggaact gatcttgaa	660
gcagttgacc ttctgtgtgc attgaattat ggcttgaaa cagaaaatct aaaaaccctt	720
tctcacaagt tgaatgcac tgccaaaaat ctgcagaatt ttataacagg aaggagaag	780
agtggccatt atgatgggag gaccagccga aaattgccaa acgactttct gacctcagtt	840
gtggatctga ttggagcagc caagagtctg ctgacctggt tggacaggtc accatttgct	900
gctgtgacag actattcagt tacaagaaat aatgtcatac aactctgcct ggagttaaca	960
acaattgtgc aacaggattg tactgtatat gaaacagaga ataaaattct tcacgtgtgt	1020
aaaactcttt ctggagtctg tgaccacatc atatccctgt cgtcagatcc tctggtttca	1080
cagtctgctc acctggaagt gattcagctg gcaaacatta aaccaagcga agggctgggt	1140
atgtatatta aatctacata tgatggcctc catgtaatta ctggaaccac agaaaattca	1200
cctgcagatc ggtgcaagaa aatccatgct ggcgatgaag tgattcaagt taatcatcag	1260
actgtgtgtg ggtggcagtt gaaaaatttg gtgaatgcac tacgagagga cccgagtgtt	1320
gttatcttaa ctttgaaaaa gcgacctcag agcatgctta cctcagcacc agctttactg	1380
aaaaatatga gatggaagcc cttgtctctg cagcctctta tacctagaag tcccacaagc	1440
agcgttgcca gcgcttccag caccatcagt acaccacca aaagagacag ttctgccctc	1500
caggatctct acattccccc tcctcctgca gaacctata ttcccaggga tgaaaaagga	1560
aaccttcctt gtgaagacct cagaggacat atggtgggca agccagtgc taagggatct	1620
gaatcaccaa attcattttt ggatcaggaa tatcgaaaga gatttaatat tgtcgaagaa	1680
gatactgtct tatattgcta tgaatatgaa aaaggaagat caagtagtca aggaagacga	1740
gaaagcacc caacttatgg caagctacga cctatatcta tgccagtgga atataattgg	1800
gtgggggact atgaagatcc aaataagatg aagagagata gtagaagaga aaactctcta	1860
cttcggtata tgagcaatga aaagattgct caagaagaat acatgtttca gagaaacagc	1920
aaaaaggaca caggaagaa gtcaaaaaa aggggtgata agagtaatag cccaactcac	1980

-continued

tattcattgc tacctagttt acaaatggat gcactgagac aagacatcat gggcactcct	2040
gtgccagaga ccacactata ccatacattt cagcagtcct cactgcagca caaatcaaag	2100
aagaaaaaca aaggctctat agcaggcaag agcaaaagac gaattttctt caaagatctt	2160
ggcctgggtg actgtgaggg ctggcttttg aaaaagaaag atgcgaagag ttacttttca	2220
cagaaatgga aaaaatattg gtttgtccta aaggatgcat ccctttattg gtatattaat	2280
gaggaggatg aaaaagcaga aggattcatt agcctgcctg aatttaaaat tgatagagcc	2340
agtgaatgcc gcaaaaaata tgcattcaaa gcctgtcatc ctaaaatcaa aagcttttat	2400
tttgcctgctg aacctcttga tgatatgaac aggtggctta acagaattaa tatgctgact	2460
gcaggatatg cagaagaga gaggattaag caggaacaag attactggag tgagagtgc	2520
aaggaagaag cagatactcc atcaacacca aaacaagata gccctccacc cccatatgat	2580
acatacccac gacctccctc gatgagttgc gccagtcctt atgtggaagc aaaacatagc	2640
cgactttcct ccacggagac ttctcagtc cagtcttctc atgaggagtt tcgccaggaa	2700
gtaactggga gcagtcagtc gtctccatt cgcaagacag ccagtcagcg ccgctcctg	2760
caggatttaa ttgagacgcc actgacaagt tcaggcttac actatcttca gactctgccc	2820
ctggaggatt ctgtcttctc tgactccgcg gccatctccc cagagcacag gcggcagtc	2880
accctgccaa ctcagaaatg ccacctgcag gatcactatg ggccataccc cttagctgag	2940
agtgagagga tgcaagtgc aaatggaaat gggggcaagc ctcgaagttt tactctgcct	3000
cgagatagcg ggttcaacca ttgctgtctg aatgctccag ttagtgctg tgaccacag	3060
gatgacgtgc aacccccaga ggtggaggaa gaggaggagg aggaggagga ggaaggggag	3120
gcagcagggg aaaacatagg agaaaaagc taatacactg cgagagttgg tagaacctct	3180
ccatgccaaa tcggatccac ttctgttggc actcaacca ttggactcac agattgataa	3240
gctaattgtt agagaattta gatcggagag agtcggtacg gcgcagactc aacatcaacc	3300
tcttgcaagc aactaaatg gcctcgtcct tgctgtttat aacagaaaac agacttgtaa	3360
aaagcttaga tcatcaagtg ttttgattg ggggcctccc aaaggatat aagaggggca	3420
ggccactctt aagaagaatg cgagctttct acattgggac tagcataaga tcaaagccaa	3480
tcaagatgga gcacagtaac agaaaactgc ggtttctgtg ggagaacaga aggggaaag	3540
gtcttaactg ggaagggct ctgtgtggta acacctcagt tgtgttctcc tgacaccag	3600
aaaagagagg gatcagcttc aataactaga aaattctggc tgtttaatgg actctttggt	3660
ggcctcttta aggcaaagca gagaagcaa attatgtatt aagtgtatt tgcattttta	3720
aaacttgacg tgctgtattg tactaaatta agtgtaatct attaaggcaa ggtatacaca	3780
atttgctttg aaacttacta tgtttattct attataaagt gtattcaggt gcaacacaga	3840
gactgctttc ggtgacatta atgaagaaaa tttctcatgc caggctttat tatagaatct	3900
tcagctaaaa tcctaacttt ctccttattt cttggcactt gtatacaagt ggtgtgcct	3960
cttagggcag gcatgagcta ttctttctg taaaatattt tgaatctata ggctgtgggt	4020
ttcatttttg aaaagtattt tgtctggatg tctttcaaac tagcttcaga tattatttaa	4080
tactatgtaa ctgggtcccc tatggctcaa tcaatattgc ttatttttct tctgtagtgg	4140
atgtgaaatt tcctttagtt ggataagata cactgtaata attttaatgc taattaatga	4200
tatttcatac tgtgcaatga acagataatt taacactgta ttttgaaatg ttttttctt	4260

-continued

cctgtcaccg cagtgtgtgg tattgcataa tgtgaatacc tgtaaaaata taaattactt 4320

aaaaataaaa atatgaccaa ttggtatcag 4350

<210> SEQ ID NO 7
<211> LENGTH: 50
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: cDNA
fragment of Maguin-1

<400> SEQUENCE: 7

ggagagagggc agcactgtaa actgaagtca aataaattca gctcttaatg 50

<210> SEQ ID NO 8
<211> LENGTH: 13
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
One-base-anchor oligonucleotides

<400> SEQUENCE: 8

httttttttt tta 13

<210> SEQ ID NO 9
<211> LENGTH: 13
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
One-base-anchor oligonucleotides

<400> SEQUENCE: 9

httttttttt ttg 13

<210> SEQ ID NO 10
<211> LENGTH: 13
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
One-base-anchor oligonucleotides

<400> SEQUENCE: 10

httttttttt ttc 13

<210> SEQ ID NO 11
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for
Maguin-1

<400> SEQUENCE: 11

cagcaagcag ttgacggga 19

<210> SEQ ID NO 12
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for

-continued

Maguin-1

<400> SEQUENCE: 12

tgaatttgac aagactcgtg gc 22

<210> SEQ ID NO 13

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for
Maguin-2

<400> SEQUENCE: 13

gggcctccca aagggatat 19

<210> SEQ ID NO 14

<211> LENGTH: 22

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for
Maguin-2

<400> SEQUENCE: 14

cccaatgtag aaagctcgca tt 22

<210> SEQ ID NO 15

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer for
cyclophilin B

<400> SEQUENCE: 15

actgaagcac tacgggcctg 20

<210> SEQ ID NO 16

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: primer for
cyclophilin B

<400> SEQUENCE: 16

agccgttggt gtctttgcc 19

<210> SEQ ID NO 17

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for
ribosomal protein S9

<400> SEQUENCE: 17

ggtcaaattt accctggcca 20

<210> SEQ ID NO 18

<211> LENGTH: 22

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for ribosomal protein S9

<400> SEQUENCE: 18
tctcatcaag cgtagcagtc tc 22

<210> SEQ ID NO 19
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer for beta-actin

<400> SEQUENCE: 19
tggaacgggtg aagggtgaca 19

<210> SEQ ID NO 20
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: primer for beta-actin

<400> SEQUENCE: 20
ggcaagggac ttctgttaa 19

<210> SEQ ID NO 21
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for GAPDH

<400> SEQUENCE: 21
cgtagcgggt gtgaaccatg 20

<210> SEQ ID NO 22
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for GAPDH

<400> SEQUENCE: 22
gctaagcagt tgggtggtgca g 21

<210> SEQ ID NO 23
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for transferrin receptor

<400> SEQUENCE: 23
gtcgtggtc agttcgtgat t 21

<210> SEQ ID NO 24
<211> LENGTH: 23

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Primer for
transferrin receptor

<400> SEQUENCE: 24

agcagttggc tgtgtgacct etc

```

23

1. A method of diagnosing or prognosticating a neurodegenerative disease in a subject, or determining whether a subject is at increased risk of developing said disease, comprising:

determining a level and/or an activity of

- (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product, in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby diagnosing or prognosticating said neurodegenerative disease in said subject, or determining whether said subject is at increased risk of developing said neurodegenerative disease.

2. A method of monitoring the progression of a neurodegenerative disease in a subject, comprising:

determining a level and/or an activity of

- (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product, in a sample from said subject and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby monitoring the progression of said neurodegenerative disease in said subject.

3. A method of evaluating a treatment for a neurodegenerative disease, comprising:

determining a level and/or an activity of

- (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product, in a sample from a subject being treated for said disease and comparing said level and/or said activity to a reference value representing a known disease or health status, thereby evaluating said treatment for said neurodegenerative disease.

4. The method according to claim 1 wherein said neurodegenerative disease is Alzheimer's disease.

5. The method according to claim 1 wherein said sample is a cell, or a tissue, or a body fluid, in particular cerebrospinal fluid or blood.

6. The method according to claim 1 wherein said reference value is that of a level and/or an activity of

- (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product, in a sample from a subject not suffering from said neurodegenerative disease.

7. The method according to claim 1 wherein an alteration in the level and/or activity of a transcription product of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or a translation product of the gene coding for human MAGUIN-1 and/or human MAGUIN-2 and/or a fragment, or derivative, or variant thereof, in a sample cell, or tissue, or body fluid, in particular cerebrospinal fluid, from said subject relative to a reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease in said subject.

8. The method according to claim 1, further comprising: comparing a level and/or an activity of

- (i) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (ii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (iii) a fragment, or derivative, or variant of said transcription or translation product, in a series of samples taken from said subject over a period of time.

9. The method according to claim 8, wherein said subject receives a treatment prior to one or more of said sample gatherings.

10. The method according to claim 9 wherein said level and/or activity is determined before and after said treatment of said subject.

11. A kit for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or determining the propensity or predisposition of a subject to develop such a disease, said kit comprising:

- (a) at least one reagent which is selected from the group consisting of
- (i) reagents that selectively detect a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and

- (ii) reagents that selectively detect a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 and
- (b) an instruction for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of a subject to develop such a disease by
- (i) detecting a level, or an activity, or both said level and said activity, of said transcription product and/or said translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2 in a sample from said subject; and
- (ii) diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, or determining the propensity or predisposition of said subject to develop such a disease,

wherein a varied level, or activity, or both said level and said activity, of said transcription product and/or said translation product compared to a reference value representing a known health status; or a level, or activity, or both said level and said activity, of said transcription product and/or said translation product similar or equal to a reference value representing a known disease status indicates a diagnosis or prognosis of a neurodegenerative disease, in particular Alzheimer's disease, or an increased propensity or predisposition of developing such a disease.

12. A method of treating or preventing a neurodegenerative disease, in particular Alzheimer's disease, in a subject comprising administering to said subject in a therapeutically or prophylactically effective amount an agent or agents which directly or indirectly affect an activity and/or a level of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

13. A modulator of an activity and/or of a level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii).

14. A pharmaceutical composition comprising a modulator according to claim 13.

15. Use of a modulator of an activity and/or of a level of at least one substance which is selected from the group consisting of (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or (iv) a fragment, or derivative, or variant of (i) to (iii) for a preparation of a medicament for treating or preventing a neurodegenerative disease, in particular Alzheimer's disease.

16. A recombinant, non-human animal comprising a non-native gene sequence coding for human MAGUIN-1 and/or

human MAGUIN-2 or a fragment, or a derivative, or a variant thereof, said animal being obtainable by:

- (i) providing a gene targeting construct comprising said gene sequence and a selectable marker sequence, and
- (ii) introducing said targeting construct into a stem cell of a non-human animal, and
- (iii) introducing said non-human animal stem cell into a non-human embryo, and
- (iv) transplanting said embryo into a pseudopregnant non-human animal, and
- (v) allowing said embryo to develop to term, and
- (vi) identifying a genetically altered non-human animal whose genome comprises a modification of said gene sequence in both alleles, and

(vii) breeding the genetically altered non-human animal of step (vi) to obtain a genetically altered non-human animal whose genome comprises a modification of said endogenous gene, wherein said disruption results in said non-human animal exhibiting a predisposition to developing symptoms of a neurodegenerative disease or related diseases or disorders.

17. Use of the recombinant, non-human animal according to claim 16 for screening, testing, and validating compounds, agents, and modulators in the development of diagnostics and therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease.

18. An assay for screening for a modulator of neurodegenerative diseases, in particular Alzheimer's disease, or related diseases or disorders of one or more substances selected from the group consisting of

- (i) a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (ii) a transcription product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (iii) a translation product of a gene coding for human MAGUIN-1 and/or human MAGUIN-2, and/or
- (iv) a fragment, or derivative, or variant of (i) to (iii), said method comprising:
 - (a) contacting a cell with a test compound;
 - (b) measuring the activity and/or level of one or more substances recited in (i) to (iv);
 - (c) measuring the activity and/or level of one or more substances recited in (i) to (iv) in a control cell not contacted with said test compound; and
 - (d) comparing the levels and/or activities of the substance in the cells of step (b) and (c), wherein an alteration in the activity and/or level of substances in the contacted cells indicates that the test compound is a modulator of said diseases or disorders.

19. A method of testing a compound, preferably of screening a plurality of compounds, for inhibition of binding between a ligand and human MAGUIN-1 and/or human MAGUIN-2, or fragments, or derivatives, or variants thereof, said method comprising the steps of:

- (i) adding a liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or fragments, or derivatives, or variants thereof, to a plurality of containers;
- (ii) adding a compound, preferably a plurality of compounds, to be screened for said inhibition of binding to said plurality of containers;
- (iii) adding a detectable ligand, in particular a fluorescently detectable ligand, to said containers;
- (iv) incubating the liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or said fragments, or derivatives, or variants thereof, and said compound, preferably said plurality of compounds, and said ligand;
- (v) measuring amounts of detectable ligand or fluorescence associated with said human MAGUIN-1 and/or human MAGUIN-2, or with said fragments, or derivatives, or variants thereof; and
- (vi) determining the degree of inhibition by one or more of said compounds of binding of said ligand to said human MAGUIN-1 and/or human MAGUIN-2, or said fragments, or derivatives, or variants thereof.

20. A method of testing a compound, preferably of screening a plurality of compounds, to determine the degree of binding of said compound or compounds to human MAGUIN-1 and/or human MAGUIN-2, or to fragments, or derivatives, or variants thereof, said method comprising the steps of:

- (i) adding a liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or fragments, or derivatives, or variants thereof, to a plurality of containers;
- (ii) adding a detectable compound, preferably a plurality of detectable compounds, in particular fluorescently detectable compounds, to be screened for said binding to said plurality of containers;
- (iii) incubating the liquid suspension of said human MAGUIN-1 and/or human MAGUIN-2, or said fragments, or derivatives, or variants thereof, and said compound, preferably said plurality of compounds;
- (iv) measuring amounts of detectable compound or fluorescence associated with said human MAGUIN-1 and/or human MAGUIN-2, or with said fragments, or derivatives, or variants thereof; and
- (v) determining the degree of binding by one or more of said compounds to said human MAGUIN-1 and/or human MAGUIN-2, or said fragments, or derivatives, or variants thereof.

21. A method for producing a medicament comprising the steps of (i) identifying a modulator of neurodegenerative diseases, in particular Alzheimer's disease, by a method according to claim 18 and (ii) admixing the modulator with a pharmaceutical carrier.

22. A method for producing a medicament comprising the steps of (i) identifying a compound as an inhibitor of binding between a ligand and a human MAGUIN-1 and/or human MAGUIN-2 gene product by a method according to claim 19 and (ii) admixing the compound with a pharmaceutical carrier.

23. A method for producing a medicament comprising the steps of (i) identifying a compound as a binder to a human MAGUIN-1 and/or human MAGUIN-2 gene product by a method according to claim 20 and (ii) admixing the compound with a pharmaceutical carrier.

24. A medicament obtainable by any of the methods according to claim 21.

25. A medicament obtained by any of the methods according to claim 21.

26. A protein molecule shown in SEQ ID NO.1 or SEQ ID NO.2, or a fragment, or derivative, or variant thereof, for use as a diagnostic target for detecting a neurodegenerative disease, preferably Alzheimer's disease.

27. A protein molecule shown in SEQ ID NO. 1 or SEQ ID NO.2, or a fragment, or derivative, or variant thereof, for use as a screening target for reagents or compounds preventing, or treating, or ameliorating a neurodegenerative disease, preferably Alzheimer's disease.

28. An antibody specifically immunoreactive with an immunogen, wherein said immunogen is a protein molecule shown in SEQ ID NO. 1, or a fragment, or derivative, or variant thereof.

29. An antibody specifically immunoreactive with an immunogen, wherein said immunogen is a protein molecule shown in SEQ ID NO. 2, or a fragment, or derivative, or variant thereof.

30. Use of an antibody of claim 28, for detecting the pathological state of a cell in a sample from a subject, comprising immunocytochemical staining of said cell with said antibody, wherein an altered degree of staining, or an altered staining pattern in said cell compared to a cell representing a known health status indicates a pathological state of said cell.

* * * * *

专利名称(译)	人类maguin蛋白和核酸对神经退行性疾病的诊断和治疗用途		
公开(公告)号	US20050153295A1	公开(公告)日	2005-07-14
申请号	US10/508343	申请日	2003-03-19
[标]申请(专利权)人(译)	VON DER KAMMER HEINZ HANES JOZEF POHLNER JOHANNES		
申请(专利权)人(译)	VON DER KAMMER HEINZ HANES JOZEF POHLNER JOHANNES		
当前申请(专利权)人(译)	VON DER KAMMER HEINZ HANES JOZEF POHLNER JOHANNES		
[标]发明人	VON DER KAMMER HEINZ HANES JOZEF POHLNER JOHANNES		
发明人	VON DER KAMMER, HEINZ HANES, JOZEF POHLNER, JOHANNES		
IPC分类号	A61K38/00 C07K14/47 C12N15/12 C12Q1/68 G01N33/53 G01N33/567		
CPC分类号	A61K38/00 C12Q2600/158 C12Q1/6883 C07K14/4711		
优先权	2002006353 2002-03-21 EP 60/365815 2002-03-21 US		
外部链接	Espacenet USPTO		

摘要(译)

本发明公开了人MAGUIN-1和/或人MAGUIN-2基因在阿尔茨海默病患者的特定脑区中的差异表达。基于该发现，本发明提供了用于诊断或预测受试者中的神经变性疾病，特别是阿尔茨海默氏病，或用于确定受试者是否具有发展这种疾病的风险增加的方法。此外，本发明提供了使用人MAGUIN基因治疗或预防阿尔茨海默病和相关神经变性疾病的治疗和预防方法。还公开了筛选神经变性疾病的调节剂的方法。

